LOW conviction · 454 dossiers

MI450/Helios rack-scale plus EPYC agentic-CPU narrative drove ATHs near $561.80 (7/1), but the July target cluster ($600 BNP, $620 BofA, $725 high) is arriving into a falling tape 20-day MA lost 7/8, chip-led Nasdaq selloff 7/17, sentiment…

LTL-recovery narrative is maturing and now fighting a company crack: ArcBest's July 16 restructuring 2% headcount cut, $76.5M impairment, brand simplification signals the freight-cycle upturn hasn't reached its own P&L, with the July 29 Q2…

Private-wireless 900 MHz spectrum re-rating that converted from FCC policy to a first full-year GAAP profit ($18.52M) and an activated buyback; the 6→10 MHz catalyst is banked and price is extended at fresh highs, so the next leg rides…

Managed-care margin recovery off the 2025 ACA blowup is largely priced (+137% off the $25.08 low into the low-$60s). The fresher driver is 2027 repricing ~14% ACA rate-hike filings (WSJ 2026-07-08) signal a hot medical-cost trend that…

AI-underwriting neobank re-accelerating as the sell-side chases the June breakout Benchmark to $475 (7/1), Citizens to $450 (7/9) after the ATH at $318.66. Q1 rev +47% to $158.4M on a record-low 1.69% past-due; the Coastal bank-funding…

Enterprise AI-server rebuild intact fundamentally (+757% YoY AI-server revenue), but the tape broke: 2026-07-15 reversed 13% from near-record high to $397 as the memory complex and SMCI sold off. Lower high vs the $475.40 ATH, momentum…

Digital-MSK profitability re-rate broke out in May and was pushed into open price discovery by the 2026-06-09 mid-quarter raise (Q2 to $200–202M, +45%; FY26 to $818–824M). But nine sell-side target hikes in two weeks plus accelerating…

AI-server and enterprise-networking pivot is real at the theme level, but HPE's own chart broke: the record +25% Q2 FY26 blowoff (2026-06-02, ATH $64.25) fully round-tripped, the ~$48 pre-print shelf failed (last observed close $43.71 on…

Medicare Advantage margin-recovery re-rate; the 2027 CMS +2.48% rate print doubled HUM off $163, but the discovery catalyst is spent and price ~$382 sits above the $304 average target. The ~2026-07-30 Q2 print is now the binary inside the…

Narrative-momentum thesis is closed: Rocket Lab agreed 2026-06-29 to acquire Iridium for ~$54/share ($27 cash + a calculated ratio of RKLB stock), EV ~$8B. IRDM now trades as merger-arb spread to ~$54 plus embedded RKLB beta not on NTN…

Freight-recovery narrative is now consensus 8+ analyst PT hikes to $280–329 in 30 days plus a CNBC transports spotlight mark a MATURING, crowded theme. The 2026-07-15 Q2 print ($1.71 EPS / $3.21B est.) is the binary that either confirms…

HBM scarcity intact SK Hynix sees shortage into the next decade, Qualcomm/Hyundai auto deals signed 2026-07-16, US push to ban Chinese memory but the tape broke: SOXX −18.6% in July, worst month since 2008, and the $854.50 shelf failed. At…

NetApp's first genuine AI re-rating (2026-05-28 Q4 print) is now digesting the ~35% gap to $192.83 has round-tripped to the ~$150 breakout-retest zone by 2026-06-26. FY27 revenue guided only +8%, no company binary until ~late-August Q1.…

BNPL reacceleration is real Q1 beat and a same-year FY26 guide raise (2026-05-06) but the consumer-fintech theme has cooled to MATURING as sell-side turns cautious: Oppenheimer cut to Perform 2026-06-29, TD Cowen stays Hold 2026-07-07…

Maturing AI-storage supercycle with sell-side still chasing: Wells Fargo upgrade to Overweight $1,100 (7/10) and Citi Street-high $1,240 (7/13). But the DRAM ETF is down ~30% and Seagate's Q4 FY26 print ~2026-07-22 is a binary about two…

Stalled single-cell franchise re-rating on the spatial/multiomics pivot: Atera (ships H2 2026), Proteintech protein capability, and a Cleveland Clinic clinical tie-up extend the story while a July cluster of analyst target raises ($40–$50)…

Silicon-photonics pivot re-rated the ADR ~3x, but the July blowoff to $28.96 round-tripped -26% to $21.25 in days while sell-side finally upgraded (Macquarie Outperform 2026-07-14) late-stage distribution behaviour. The 2026-07-29 Q2 print…

The AI memory/storage supercycle that re-rated WDC has flipped from accelerating to breaking: the DRAM ETF is down ~30% in under a month (2026-07-13), CXMT's $10B Shanghai IPO (2026-07-15) plus SK Hynix/Samsung supply signals revived…

Parabola fully broken: ~$101.58 on 2026-07-18 is -57% from the $233.67 high, and the $150 shelf that defined the uptrend is long gone. Fundamentals still accelerating (FY26 guide >$1.1B) but insiders sold ~$17M into the top and the…

Grid/advanced-conductor supplier to data-center and utility power; backlog still +40% YoY (~$280M), but the tape kept breaking after the 2026-05-28 beat-and-soft-guide and a late-June Russell index removal piled on passive selling. Now…

Operating story and equity have decoupled: >1 GW contracted and ~$31B backlog, yet the stock halved from $49.65 (2026-05-28) to $25.79 (2026-07-17) on a ~$2.7B debt load, widening GAAP losses and CoreWeave concentration. Price now sits on…

The July 15-16 $1B convertible plus the slip of initial commercial direct-to-device service into 2027 broke the "2H26 revenue" leg the June rebound was built on; a 17% one-day flush to $55.01 and a fading +12% bounce mark this as a…

InP substrate supplier one layer upstream of AI optical interconnect fundamentals still accelerating on the 7/2 Coherent master supply deal ($22.29M prepay) and $100M backlog, but the tape has round-tripped >50% off the $143 ATH toward the…

The $100 shelf broke market cap $44.79B (06-29) to $38.27B (07-16), roughly $88/share, ~35% off the $135.24 January high, and it fell through the best nuclear headline flow of the cycle (NJ's $24B AP1000 plan, the $17.5B federal loan…

Nuclear-for-AI narrative has broken down, not paused: -35% in H1 2026, 52-wk low $228.63 (07-01) on the Calpine lock-up release, then NY's 2026-07-14 statewide moratorium on ≥50MW data centers froze co-location upside across CEG's biggest…

Stablecoin leg is being marked down: JPMorgan cut COIN/CRCL EPS on 2026-07-14 over Hyperliquid economics, and Piper cut to $155 on 07-15, breaking the old $180 bear anchor. Offsetting it, a Senate CLARITY Act vote is flagged for the week…

OCC national trust-bank approval (2026-07-10, +12% to ~$70.82) fully round-tripped in three sessions $60.46 on 2026-07-17, below the $63 pre-news close. Open USD, a 140-firm consortium including Visa, Mastercard and Coinbase, launches…

Neocloud de-rating is confirming, not contested: Meta's reported ~$10B Anthropic compute deal (7/18) turns the disintermediation threat into a signed transaction, shares are -30% in a month, and desks are cutting (Mizuho $100, Macquarie…

The gov-capital quantum leg has broken. IONQ lost the $44 spring base and then $40, is on a seven-week losing streak and ~36% off its June level, as Wolfpack's Pentagon-earmark thesis reasserted and Morgan Stanley cut its stake below 5%.…

Neocloud re-rate has fully round-tripped: $33.62 close 7/17, -42% in 30 days, late-May Microsoft breakout base surrendered. Contracts intact ($9.7B MSFT, prepaid tranches) but Q3 AI revenue was only $17.3M vs a $3.4B ARR ambition, and…

Narrative flipped from capex-defense to compute-monetization: a reported $10B/2yr Anthropic data-center lease (7/17-7/18) turns Meta's buildout into contracted external revenue, confirmed by NBIS and IREN derating on "Meta Compute"…

Bitcoin-treasury flywheel is mathematically shut: basic mNAV 0.62x (7/6) means issuing equity now destroys BTC-per-share, and Strategy raised $467M on 7/13 while buying zero bitcoin. Capital funds a 12% STRC coupon and a $3B reserve…

The AI-memory leg MTUM rotated into at the May reconstitution has rolled over: SOX -20%+ from its June peak, memory names in a bear market, and the fund closed $302.09 on 2026-07-17, below the $310 shelf that defined the…

Nuclear-microreactor narrative has stopped converting news into demand: a Truist Hold/$22 initiation (7/14) and a Virginia consortium announcement (7/17) landed inside four sessions and NNE still printed a fresh 52-week low at $15.78…

Momentum leg is dead: OKLO sliced its 52-week floor at $44.16 on 2026-07-16 to $41.03 (-79% from the Oct-2025 $193.84 peak, -28% in a month) and capital is rotating to peers. Everything now hangs on one dated binary Groves reactor…

The post-SpaceX-IPO unwind has extended, not stabilized: PL broke the $23 shelf on the 7/16 -7.8% flush and trades ~$22.58, roughly 56% off the $51.40 May peak, with the 50-DMA ($35.40) and 200-DMA ($30.60) far overhead. Record…

Deployment-layer story still funds a Buy consensus (~$181 avg PT, Ives $230), but the June-July bounce off the $106.37 low stalled under $135 and rolled to $131.75 (2026-07-17) with the 200-DMA ~$156 overhead. Franco-German Arcadia…

The policy leg is done: QBTS lost the $20 shelf on 2026-07-13 and sits near $16.70, -29.4% MTD and ~64% off the $46.75 high, with the whole quantum cohort printing lower lows and inverse quantum ETFs up to +108%. Sell-side still carries a…

The $10 shelf broke: QUBT closed $7.80 on 2026-07-17, market cap down to ~$1.76B on $4.33M TTM revenue, while the quantum basket de-rated on a risk-off tape. Early-July authorization to 450M shares plus a $118.52M/13.54M-share registration…

Quantum pure-play basket is in outright hype-cycle deflation: RGTI ~$14.19 (2026-07-17), -27% MoM, and the $14 shelf that held the May CHIPS-stake gap and the June executive-order pop has broken. Inverse quantum ETFs printing +108% and the…

Sovereign-capital binary: the KORUS $200B package lists nuclear among strategic sectors and reportedly eyes a NuScale reference plant, but the leg is undated and unsigned. June's ~$14 pop fully round-tripped; shares press the $8.85 52-week…

Nasdaq-100 inclusion flow catalyst fired and faded into a sell-the-news; SPCX is now an unbased $1.77T post-IPO decliner (a post-IPO buyer down ~23%) in the Figma/Circle retreat cohort, with lock-ups ahead and China closing the…

Optical-foundry leg re-rated on the 2026-06-18 5M-coherent-PIC Marvell shipment and 2026-06-15 IQE InP deal, but both are digested, sell-side re-rated to $300–335 on 2026-05-14, and no company catalyst lands before the ~early-August Q2…

Optimus/Robotaxi leg is expanding geographically (Miami + Texas fleet, BofA $460) but the tape broke down anyway the Musk-complex bid inverted as SPCX retreats from post-IPO highs, ARKK bleeds assets, and Chinese brands took a record 16.5%…

Mine-to-magnet story intact, tape broken: price ~$11.48 vs the $16.12 used to value VAC's 65.853M new shares, market cap $3.86B→$2.84B since 2026-06-23. VAC doesn't close until early 2027, so ~27% dilution is priced now and magnet revenue…

Power-for-AI story intact but the tape is not: ~$155.67 (2026-07-17) sits on a $154 50-DMA that is still below a declining ~$172 200-DMA, 29% under the $219.81 high, while CNBC Final Trades name it four times in a month. Aug 7 Q2 print is…

Butterfly Embedded chip-licensing story got marquee validation Midjourney's up-to-$74M/5yr full-body scanner on 40 Ultrasound-on-Chip modules (2026-06-18) plus 2nd partner Aleph Neuro (2026-06-25). Fundamentals still accelerating, but the…

The optical-interconnect leg has rolled over: COHR is ~-35% from its 2026-06-02 closing ATH of $426.89 to $277.60, with the whole photonics basket (AAOI, LITE, FN) taking repeated 8-17% down days since May. Fundamentals still compound…

Optical/AI-infrastructure demand is intact (Q1 Optical +36% YoY, Amazon/Meta/Nvidia agreements) but the price structure broke: all-time high $271.78 on 2026-06-30 to $154.61 on 2026-07-17, a 43% drawdown on heavy volume with CEO-level…

Legacy crypto-financials name re-rating to AI-data-center landlord: Phase I ~200MW at the Helios campus was delivered to CoreWeave on 2026-07-06, turning the ~$4.5B/15-yr lease from promise into live contracted revenue while shares still…

Bitcoin-miner-to-AI-datacenter-landlord re-rate is now financed fact ($4.25B IG notes 6/4, ~$16.8B contracted backlog), but the momentum leg rolled from ~$127 to ~$105 as peers WULF/IREN captured the marquee Anthropic tenant deals (7/6)…

Foundry-revival re-rating has unwound hard: INTC -31% in July vs TSM -15%, the ~$92 announcement shelf is gone, and SOXX just posted its worst month ever versus software. The 2026-07-23 Q2 print (18A yield, foundry loss, client CPU share)…

Oral STAT6 degrader (KT-621) re-rated on early BROADEN2 enrollment (6/25) and the $10.9B AbbVie–Apogee read-through, but the analyst upgrade cycle topped with RBC's 7/13 downgrade to neutral and the binary topline is 2H-2026 a maturing,…

Supply-security leadership trade has broken: China's 06-22 export listing named MP as a target of curbs, the $56 base failed, and price slid to ~$45 (07-17), ~54% off the 2025-10-14 high. Sell-side is cutting into weakness (DB $61,…

Neocloud narrative has inverted: Meta Compute (7/1 Bloomberg) turned the biggest customer into the biggest competitor, and NBIS is -38% from its 6/18 close high of $286.69 despite a $1B Reflection AI deal and a $775M non-dilutive…

July killed the falling-wedge breakout: SOXX fell 18.6% (worst month since 2008) and 19.95% vs IGV (worst on record), Apple retook the market-cap crown, and Kimi K3 re-opened the compute-efficiency question. Earnings estimates held the…

June breakout fully round-tripped: ATH $386.46 (6/30) to $279.85 (7/17), now below the 50-DMA at $294.49. The tell is non-participation TSMC raised capex to $60-64B and ASML guided up twice on 7/15-16, and ONTO closed the week at its…

The gamma-squeeze/index leg is over: PURR is -42% from its 6/1 high of $11.62 to $6.68 (7/17), through the $7.70 shelf, and now trades at roughly 0.78x the value of its 17.6M HYPE stack a treasury premium that has flipped to a discount,…

The data-center re-rating already failed: QCOM spiked to a 52-week high of $259.92 on the ~2026-06-24 Investor Day $15B-by-2029 guide, then gave back ~34% in 17 sessions to $171.78 as Hold downgrades and Apple modem-attrition math…

BTC-to-AI-landlord re-rating is structurally intact AMD $311M/50MW Rockdale lease, $33.2M Q1 data-center revenue, Citi reiterated Buy/PT $28 on 2026-07-08 but the miner complex rolled over on a Q2 crypto rout and "fresh AI-pivot headwinds"…

Iridium re-rating leg is rolling over: Piper Sandler's 7/16 Neutral initiation at $83 came in below spot and every raised target, the 7/13 support shelf broke, and the 7/14 AVac hot-fire pop was faded inside two sessions. Sector-wide…

Solar/BESS EBOS name re-rated as a 2nd-order AI-datacenter-power play on a record $758M Q1 backlog and the multi-GW ON.energy deal; price reclaimed the $10 pivot but consensus PT sits at spot (~$10.63 vs $10.02), so the confirmed…

Two of three lead binaries (SPY001, SPY002 anti-TL1A) printed potential best-in-class; the stock absorbed a ~$399.7M director-fund block sale and sits back near its ~$102 ATH (~$95). Next legs SPY003 IL-23 Part A (guided mid-2026, overdue)…

Post-data digestion, not acceleration: the 92% ORR combo print is fully paid for and the tape has faded from $32.90 to ~$27.7, below the $30.00 June secondary. Sell-side keeps marking up (JPM Overweight $46 on 7/15, Mizuho $40 on 7/17)…

Q2 (7/16) beat on every line $40.20B rev +33.7% YoY, 67.7% GM, FY26 guide lifted to >40% growth yet the tape punished the capex raise to $60–64B and the 3–4pp 2nm margin dilution, driving the worst selloff since 2022 and a two-month low.…

Conway extract/RTD platform inflecting capex to cash: Q1 (5/07) beat revenue with record adjusted EBITDA, FCF-positive-H2 guide reaffirmed, and a 6/30 debt-maturity extension cleared the near-term refi wall. Stock re-rated ~the published…

The Iran-war crude premium has fully unwound: WTI crude ~$69 (Jul 2) vs $100+ in May after the June 17 US–Iran MOU reopened Hormuz, and W&T which never rallied on the spike has broken its $4 shelf to $3.11 (Jul 1). A hedged,…

Q2 (07-16) missed at $2.12 vs $2.25 and management cut the FY alumina outlook on Pinjarra refinery problems five sell-side target cuts in nine sessions (BMO $55, JPM $52, WF $71), zero raises. The Hormuz premium is gone, the next catalyst…

Apple retook the world's-largest-company title from Nvidia on 2026-07-17 after a $1.45T two-month swing, powered by rotation out of AI semis plus a $30B Broadcom custom-silicon deal and reported AI-chip M&A hunting. The re-rate is now…

ZEVASKYN commercial ramp inflecting: Q1 revenue of $8.7M nearly doubled the ~$4.57M consensus and management floated monthly profitability by June. The mid-August Q2 print (~2026-08-12) is the binary that confirms or breaks the…

Obefazimod's positive Phase 3 UC maintenance data (June 29) completed a de-risked oral pivotal package, but the binary has already fired: a +36% gap to ~$130 plus an $800M raise at $125 mark this as a MATURING, sell-side-caught story, not…

Life-settlements franchise attached itself to the RWA-tokenization narrative on 2026-07-07 (100+ policies on-chain, targeting the $224B secondary market by year-end); Q1 beat and raised FY adj-EPS guide to $1.00–1.05. But price rejected…

Sentiment-beta proxy on the U.S. cannabis-reschedule trade, but a Canadian LP with no U.S. THC ops the structural laggard. Broke to a fresh $2.63 52-week low; FY2027 guided as a "reset year" with revenue declining on a ~30% Canadian…

the headlines that drove it to $8.15 in June no longer bid it. A glut overhang broke the beta into a loss-making frac core.

June memory/HBM semicap re-rating that carried ACLS to a $193.78 high has broken early-July profit-taking cut it ~15% below the June shelf and 50-day MA (~$160) to ~$135–143. FY2026 revenue still guided flat, so the remaining bull case…

Analog cyclical-trough plus the $1.5B Empower AI-power option fired and fully repriced in one week around the ~2026-05-20 Q2 print; nine weeks on, four more target raises (Cantor $550, Keybanc $525) are sell-side catch-up on a published…

ADVA-merger margin turnaround confirmed (Q1 5/4: rev $286M +15.5%, non-GAAP GM 43%), but the ~$7→$20 run has rolled over down ~20% on the month to ~$13, losing the $14–15 shelf while the AI-optical cohort (CIEN/LITE/COHR +100% YTD) rips…

Datacenter-power picks-and-shovels re-rating has matured into mainstream coverage: the late-June upgrade wave (Wells Fargo bear-to-bull Overweight $465 on 07-01, Susquehanna Street-high $535 on 06-30) confirms the 800V HVDC rack story…

Frac-sand legacy name pivoting to behind-the-meter gas power for AI data centers, but the post-Caterpillar re-rating has round-tripped: shares lost the ~$15 breakout base to $14.39 (7/10), no new PPA since 4/1, and a Russell growth-index…

Listed pure-play gas EPC on the AI data-center power buildout theme ACCELERATING ($2.8B backlog, 4.1+ GW gas pipeline) but the stock blew off to an $805.75 ATH and has round-tripped the entire Q1 pop, closing $630.32 on 2026-07-10 and…

Hospitality vertical-SaaS recovery has re-accelerated into its print: AGYS ran ~+18% to $108.98 (2026-07-10) off the June ~$92 base, clearing the two lowest analyst targets ($100/$110) ahead of a confirmed 2026-07-27 Q1 FY2027 binary that…

Semiconductor-IP royalty re-accel is fundamentally intact (Q1 variable royalties +67% YoY, FY26 guide raised, fresh SiEngine/Li Auto auto wins), but the stock printed a $48.59 blowoff top (6/30) and reversed ~29% in a week, losing the ~$39…

USRC-sponsored VOICE outcomes trial (2026-06-30) stopped early for success Vafseo cut dialysis hospitalizations vs ESAs with neutral mortality, a hard-data adoption catalyst for this ~$1.40 renal micro-cap. But price sits near its 52-week…

Radioligand-therapy pure-play trading on coverage and flow, not data; ~64% above its Jan-2026 $18 IPO on a June initiation cluster (RJ $40, HCW $35) plus an Eli Lilly halo. The accelerant is fading JPM maintained Overweight at the cohort's…

Analog/power-IC re-rate on the AI data-center power-attach story stays analyst-confirmed Mizuho PT $67 (6/29), TD Cowen $70 (6/22) after the record ~$60 print but the stock sits ~10% above the ~$54 consensus fair value, ~2x GF Value, is…

Profitable-MA-disruptor narrative broke on 2026-07-08: a whistleblower suit from a former Chief Transformation Officer alleges the +88% adjusted-EBITDA inflection was manufactured by reclassifying opex as capex across FY2024-25. Shares…

AstroNova is a closed narrative: Arcline's $29.00 all-cash take-private (announced 2026-06-17, ~$272M, Q3-2026 close) hard-caps the stock. The 200%+ pop was a one-time buyout gap, not an accelerating story what remains is a thin merger-arb…

Legacy ethanol/specialty-alcohol pivot re-rated ~6x off $0.92; Russell 2000/3000 add (eff. 2026-06-26) drove a new 52-week high of $6.11 in early July, but that passive-flow catalyst is spent and price has faded to ~$5.63. Maturing…

WFE toll-collector on the AI-silicon buildout best month since 1975 (+54%) and the most overbought reading in its history, with the sell-side PT cluster escalating to $740-900. Narrative still ACCELERATING, but the tape is parabolic and…

Edge-AI silicon small-cap whose 2026-05-12 Q1 beat + Q2 guide-raise drove a parabolic to an $85.77 ATH (May 26), then a -12.4% distribution day (Jun 5). Catalyst is spent, no binary lands until the ~Aug Q2 print, and price sits above the…

Box-office recovery drew its first sell-side nod Macquarie lifted its PT to $2 (Neutral) on 2026-07-08 and price is stabilizing above the 200-day MA. But a Neutral target sitting at the $2 shelf implies no upside; ~1B shares and ~$4B net…

Post-parabola OSAT laggard rebuilding under the $74-75 shelf after the 2026-06-16 TSMC 10-yr Arizona deal. Every catalyst since April has been sold (the beat -8.6%; the deal pop faded to -8.5% by 06-25), and the 2026-07-27 Q2 print is the…

Healthcare-staffing cyclical recovery, real but MATURING: shares printed fresh 52-wk highs ~$32.5 (+105% YTD off $15.77) yet sit ~30% above the ~$25.29 avg PT with a soft Q2 guide and no upgrade cluster. Extended entry into overhead target…

Beaten-down product-analytics SaaS re-rating as an "AI analytics" turnaround: net retention inflecting toward a 115% target, agentic-AI/MCP product cycle, and a Statsig deal adding $16M ARR. Raymond James Strong Buy ($10 PT) sparked a…

AWS reacceleration (+28% YoY in Q1, 15-quarter high) has not converted into tape shares ~$245 vs the May high of $278.56, pinned on the 50-day with megacap flow rotating to IJR/IJH/RSP. KeyBanc lifted its target to $335 on 2026-07-16…

Pure-play Jemperli/imsidolimab royalty stub since the April spin-off; the entire equity now hinges on the 2026-07-14–17 Delaware Chancery trial on royalty reversion and rate preservation now 1–3 trading days out. A binary legal verdict,…

Precision-psychiatry re-rate that has already run ~10x off a $2.50 low to near its $28.44 high; funded through 2029 on the March $120M PIPE, but every binary readout (ALTO-300, ALTO-100, ALTO-207 in TRD) sits in 2027 the tape near highs is…

Post-parabola dormancy: the April–May "second-order AI power-semi" re-rate (~3x to $54.34) is fully realized, priced above the $30.50 consensus PT, with no fresh AOSL catalyst in five-plus weeks. Next binary is the ~early-August FY26-Q4…

AbbVie's confirmed $135.11 all-cash takeout (announced 2026-06-23, ~$10.9B, ~49% premium to the $90.38 pre-bid close) caps the stock at the bid and extinguished the IL-13 momentum leg; the downgrade cluster reset ratings to Hold at the…

Royalty re-rate leg has broken: HSBC cut to Hold with a $315 target (7/14) behind New Street's 6/18 Neutral, price has retraced through the the published invalidation level post-Computex base and the June low to a $295.18 reference (7/13),…

Bitcoin-treasury premium fully inverted: Strive keeps buying (19,882 BTC as of July 2, latest lot @ $59,850) into record BTC ETF outflows while mNAV sits at a ~0.78x discount, so the $2.55B ATM now destroys NAV per share. Peer treasury…

Between-catalyst psychedelic leader jolted by a 2026-07-06 volume spike on an unconfirmed M&A-blog takeout rumor, stacked on Russell 2000/3000 inclusion (effective 2026-06-29) and a Canaccord PT bump to $17 (2026-07-07). The one hard…

Post-TrojAI AI-security re-rate still accelerating but now MATURING and extended: ATEN at all-time highs (~$36.30, June 30 close $37.36) trading ~15–20% above the blended $30–32 consensus and above every desk but the lone $45 bull. Aug 5…

The cyclical-bottom trade has unwound: after a $90.16 June high, ATKR trades ~$72.68, below its $78.03 50-day and pressing the $69.69 200-day, with RBC cutting its target to $76 (7/16) and Wall Street Zen going to Hold (7/18). The…

Gold/copper producer basing $53–$76 — below its broken ~$72 shelf after a ~45% drop from the $110 high. Q2 production slipped 8% QoQ (first sequential decline after a record Q1) as gold stalls in the low-$4,000s and sell-side trims targets…

Driverless-freight commercialization keeps widening (McLane Dallas–Houston live, ~10 Sun Belt lanes, 200+ truck year-end target), but the tape is rangebound: a 2026-07-01 +9% spike to $7.45 on Craig-Hallum's $18 call and a clean safety…

All-cash $25.00 take-private of Avanos by American Industrial Partners is now a near-closed pin: all regulatory approvals obtained 2026-07-02, leaving only the 2026-07-22 shareholder vote before an expected close by 2026-07-27. The spread…

TAVR disruptor whose de-risking catalysts (CMS CED 4/28, first US patients 5/5, French ANSM clearance 6/8) are now exhausted; price ran to a fresh ~$11.06 high then faded to $9.77 (7/10) on no news, back near the in-the-money $250M ATM…

Value-unlock special situation, not momentum: ~$10.90/share net cash, Politan (~10%) on the board, and portfolio simplification now executing B Medical Systems divestiture closed Jul 8. But the +60% bounce off $15.93 has stalled in the…

Beat-and-raise fired 2026-07-08 Q1 adj EPS $1.85 vs $1.69, FY27 guide lifted twice on Metal Coatings momentum but the catalyst is now behind the stock, which sits at all-time highs (~$157), ~23x forward and above consensus, with Wells…

Distress jumped from the Idesa JV to the parent: ~2026-06-29 Braskem S.A. won a 60-day creditor standstill, Fitch cut to C and S&P to D (default), and JPMorgan capitulated to Neutral (2026-06-30) as creditors rejected management's plan and…

Fully re-rated small-cap CPaaS squeeze: +360% YoY to ~$75, ~5% under the $79.08 high. The mid-June $275M 0% convert broke above its $72.64 strike instead of capping the tape. Riley lifted its target to $85 on 2026-07-09 but price has…

Lemonis "Everything Home" roll-up accelerating on deal cadence (TwoPonds, Affirm BNPL, Tokens.com, all ~2026-07-01), but the BBBY tape stays pinned near its 52-week low (~$5.83 vs $4.26) a story-stock value trap until price reclaims…

Broken-growth AID-pump name in a pre-earnings holding pattern: the ~2026-07-28 Q2 print is the binary that decides whether new patient starts re-accelerate or post a second straight sequential decline. June's ~$14 relief bounce off the…

Rotation-passenger thesis is dead: BBWI broke its multi-year base and sits ~36% off its high near 52-week lows while the tape makes records. Only live leg is a nascent self-help turnaround Ulta wholesale launch 2026-07-12, Consumer First…

Tape flipped since early July: BBY broke to a fresh 52-week high $87.35 (~$85.41 on 2026-07-17, +27.6% YTD) on RGB-LED TV exclusivity plus an AI-PC/MacBook refresh cycle. But price sits ~8% above the $79.15 consensus target while Loop…

Bifunctional EGFR/TGF-β narrative in HPV-negative head & neck cancer stalled after the ASCO 2026 three-year-OS re-rate: $27.76 close is ~10% off the $30.99 high on roughly half prior turnover, consensus PT ~$31.46 sits only 13% above spot,…

On-site SOFC power for AI datacenters is ACCELERATING and cluster-confirmed (Oracle 2.8GW, Nebius $2.6B, FERC large-load order, record $328.91 on 6/18), but two July short reports Hunterbrook (7/8) on China-free supply, Crossroads (7/9) on…

The premium-to-book re-rating has unwound: BH ~$384 (Jul 17) sits back under the ~$401/Class B book line while CBRL rallied to $53.61 the holdco is falling as its main asset rises, re-widening the discount. A $500M ATM with ~$485M undrawn…

Spec-biotech de-rate reversal on opakalim epilepsy data, now >110% off the $7.48 low to ~$16; RISE3 enrollment complete and shares shrugged off a BofA Underperform ($11), but the value-driving topline is unscheduled 2H-26 and a dilution…

Left-for-dead pivot re-rated ~6x off $4: oral NLRP3 inhibitor BGE-102 reframes BIOA as a "statin-for-inflammation" CV play after median 86% hsCRP cuts in Phase 1. QUELL-CV Phase 2 topline (2H 2026) is the binary. Now grinding fresh 52-week…

Post-miss +46% V-recovery has rolled over ~$44 from a ~$48.75 June high, never retesting the $53.53 ATH. The tell: fresh $500M buyback authority funded by the June 19 €900M notes landed and the stock still faded. S&P cut the outlook to…

Casual-dining turnaround already re-rated: seven straight quarters of traffic growth under CEO Tick, but Q1 comps decelerated to +2.4%, FY guide is just +1–3%, price sits ~30% above every analyst PT, and insiders sold the June high. Mature…

The +80% Q1 turnaround re-rate has fully round-tripped from the $6.57 high: BLDP lost the 20-EMA near $5.00 and the $4.80 breakout shelf, sits in a catalyst vacuum until the 2026-08-12 Q2 print, and Susquehanna's 2026-07-10 cut to $3.50…

Argentina disinflation/credit-recovery basket; BMA is the best-capitalized domestic vehicle. Sequential CPI is genuinely improving (3.4%→2.6%→2.1%→1.9% MoM, Mar–Jun 2026), but the tape has gone nowhere since the Oct-2025 midterm leg ~$90…

Post-2026-06-23 reverse merger into Serapha Bio, this stopped being an oncology stock. The tradable object is a defined ~$44–48M pre-close cash dividend plus a ~3.7% stub in the AATD base-editing NewCo (future ticker AATD), not an…

Broken protein-staple turnaround; the June–July bounce off the $7.82 low is oversold mean-reversion, not re-acceleration. A new CEO effective July 29 and Stephens' $20 PT are scaffolding the ~Aug 3 Q3 print is the binary that validates or…

Post-ASMS product-cycle re-rate has matured into a based-out momentum leg: the low-$40s→$64.54 June run held near $55, and the sell-side kept chasing Guggenheim $53→$70 (2026-06-29), Leerink Outperform $70 (2026-07-07), Citi Neutral $60…

Drive-thru coffee comps re-accelerating (Q1 +8.3%, FY guide raised) and the sell-side is now catching up Stephens initiated Overweight $80, Morgan Stanley to $88 in mid-July. But June's run to ~$72 cooled to the mid-$60s, and the…

Broken wrapper on an accelerating underlying: WhiteFiber (WYFI, ~70% owned) held $38.50 on its 7/9 cross-datacenter networking milestone, but BTBT de-rated to $1.69 toward its $1.25 52-week low blowing the SOTP discount out to ~54% (the…

Spring miner-to-AI re-rate has fully unwound: BTDR lost the $15 shelf to $12.56 (2026-07-09) as AI-cloud ARR plateaued at ~$69M for a 2nd month. A signed-but-not-effective Tydal colocation lease (2026-06-29) and a $36M Nevada plant are the…

Middle East oil premium re-firing: the US reimposed Iran sanctions on 2026-07-07 after Hormuz tanker attacks and WTI bounced to ~$72. But it's a contained-conflict bid, not a supply shock BTE is still below its 50-day and this is an…

Broken IPO (~$5.13 vs $18 Jan listing) that just printed a fresh all-time low at $4.67 as the 2026-06-17 buyback bounce faded rolling into a 2026-07-21 lockup unlock (~10 days out), a new 15% layoff, and a fresh IPO-period securities class…

De-levering small-cap orthobiologics turnaround, now maturing: the July-2025 refi killed the 2026 debt wall, margins inflected above 20%, and the stock re-rated ~+117% to within 4% of its 52-week high. The easy money is largely priced; the…

Take-private premium is bleeding while sell-side chases it higher: price slipped to $27.25 (2026-07-17) from $28.41 (2026-07-02) even as KBW went to $31 and JPM to $30. Nothing is signed, and the 2026-07-30 Q2 print (guide $485–490M,…

CAN-2409 narrative re-armed on the 2026-06-30 AURORA Phase 3 launch in post-ICI NSCLC a second pivotal program in a far larger indication plus an ex-AstraZeneca lung CCO hire; the stock cleared the old $9.27 high to an $11.36 peak, then…

Casual-dining re-rate got a genuine second leg: Citi's 2026-07-10 raise to a street-high $90 (Buy) on a rewards/app traffic-inflection thesis gapped shares 7% to all-time highs (~$86, 52wk high $86.66 on 2026-07-18). For the first time the…

Post-earnings drift has cut the stock ~19% from its pre-print ~$14.51 to $11.81 (2026-07-10), slicing the low-$13s June base as the spent Q1 catalyst left no momentum leg. Cheap on forward numbers (~7.7x, ~$57.8M tariff-refund optionality…

Capital-light auto marketplace compounding per-share via a 29%-of-float buyback and steady ~15% marketplace growth, but the theme is MATURING, growth is decelerating (Q2 guide +11-14% vs Q1 +15%), and the 2026-08-06 print is a binary with…

Q3 FY26 beat + raised FY26 guide ($3.27–3.30B vs $3.25B) confirmed the legacy-diner turnaround, but the catalyst fired five weeks ago, the rotation cooled to maturing, and the next print is ~September. A 2026-07-13 13G/A (D.E. Shaw…

Deal-pinned cash merger-arb, not a momentum trade. Knox Lane taking CCRN private at $13.25 cash; HSR cleared 2026-06-22 for both the merger and the locums sale, leaving only the 2026-07-16 shareholder vote. ~0.3% capped upside vs ~25%…

The ROAD-Act homebuilder bounce (~$55→$63) has saturated into mainstream coverage; Zelman cut CCS to Underperform 7/7 as the most credible housing bear, and demand keeps softening (June HMI 35, Q1 contracts -11.6%). The 7/22 Q2 print is a…

Humanoid-robotics de-SPAC: Churchill XI merges with Agility Robotics (~$2.5B, Nvidia/Amazon-backed, re-lists as AGLT). Theme intact, but the tape is an RSI-98 filing-driven blow-off that has since gone quiet with no dated catalyst until…

Multi-year Medicare overhang lifted: finalized MolDX LCD (2026-07-16, effective 2026-08-30) affirms surveillance dd-cfDNA coverage for kidney/heart/lung transplants, driving a ~+28% re-rate to a fresh 52-week high near $40. Structurally…

Post-blowoff digestion: after a ~4x run to a $94.31 ATH (2026-06-29), a $73 secondary (4.6M shares, ~$336M, closed 06-26) capped the parabola and CDNL now trades below the deal price near $68 under its $63 average analyst target.…

Second-order AI-server reseller whose ~37% recovery off the $97 low has stalled: a mid-July push to $144 round-tripped to $133 by 2026-07-17, right in the fairway of the ~$145 consensus target. The re-rate (JPM, MS $170, Citi $145) is…

Analyst-confirmed profitability inflection (Q1'26: adj-EBITDA +$4.0M, +$6.2M op cash, +24% product rev) in a 25-year blood-safety grinder but the 2.7x off the lows is largely spent and price is pinned at 52-week highs (~$3.19 vs $3.21).…

Fallen drug-development software name grafting an NVIDIA agentic-AI headline onto a broken tape: May 11 FY26 guidance cut ($0.35–0.41 EPS), CFO exit July 14, and a faded July NVIDIA pop leave price ~$6.90 rolled over below all MAs near…

Federal cannabis rescheduling is a live but dissipating binary: the DEA adult-use Schedule III hearing (opened 2026-06-29) closes 2026-07-15 with written briefs and no verdict, and the ALJ recommendation is undated afterward all seven…

The 1.6T WaveLogic demand cycle is intact at the order book, but the trade has broken: $627.00 (06-02) to ~$370 (07-18) is a ~41% de-rating, and the $455–$467 shelf that framed the prior read is gone. Multiple compression from 54x forward,…

Single-asset immunology binary: barzolvolimab (anti-KIT mast-cell depleter) has both Phase 3 CSU trials fully enrolled six months early, with topline Q4 2026 the coin-flip. Stock ~$35 vs $53 median target, but the tape is range-bound in…

GOES re-rating has fully round-tripped: ~$9.79 vs the $16.70 52-wk high, -22.3% in a month, price now BELOW four of five freshly cut targets. The $400M DoD award (7/1) was sold; Weirton transformer plant was cancelled in 2025 and POSCO is…

The May earnings-miss squeeze has fully round-tripped the ~39% pop off the 2026-05-06 Q2 print has bled to the mid-$30s (~$33.77, 07-10 close), below the ~$36 gap base, as BEAD revenue slips to FY2027 and insiders sell into the plan. The…

Court-ordered 4.5-Star recalc (2026-06-10, +18.9%) is a spent binary that gapped CLOV above its $4.23 52-week high, with no company catalyst until the ~early-August Q2 print. The 2026-07-06 Elevance copycat suit shows the Star-rating…

CNS gene-therapy delivery arms-dealer for uniQure's AMT-130 (Huntington's BLA planned Q3 2026). The June re-rate held near $18.72 rather than reverting, but the near-term binary is spent and the theme has cooled to maturing no dated…

Sell-side cluster finally formed Citi Buy/$45 and Mizuho Outperform raised to $41 (both 2026-07-13) joining JPM's Overweight, plus first Mexico restaurant announced but the ~2026-07-22 Q2 print is three days out and no weekly 20-EMA…

Broken-medtech value name flipped to a live takeover play: the board is weighing strategic alternatives including a sale after PE interest, gapping the stock from the mid-$30s to ~$42 (+10.5% after-hours, ~2026-07-11). M&A optionality is…

Resolved special situation: Lilly closed its $38.00 cash plus up-to-$9.00 non-transferable CVR scheme on 2026-06-24 after the 2026-06-22 High Court sanction; last Nasdaq ADS trade was 2026-06-23 and shares have delisted and are…

Coconut-water category leader re-rated ~+130% off the $31.79 low on a real Q1 FY26 blowout, but that catalyst is now ~10 weeks stale and the swing-momentum signal round-tripped (bought 6/3, sold 6/18). The 2026-07-09 Piper PT raise landed…

Post-fraud recovery (+~115% off the $4.58 low) has stalled: a 2026-07-01 +9% pop to $11.57 faded back under the 50-day (~$11.14) to ~$10.08 by 2026-07-08 on volume 53% below average. Only live optionality is the delayed Management Services…

AI-compute test picks-&-shovels re-rate (Eclipse xPU handlers + Neon HBM inspection) is now a broad sell-side chase three PT raises in a month to $65–80 (TD Cowen $80, Baird $65, Stifel $70) with the stock near its $70.47 ATH after…

Post-Anywhere synergy inflection has re-accelerated: COMP ripped ~+30% off the June AG-probe low near $9.78 to ~$12.70 on a doubling in Coldwell Banker luxury demand and Barclays' $12→$15 upgrade. Now stretched into a binary ~2026-07-29 Q2…

Lifyorli oncology launch (approved 2026-03-25, NCCN preferred) re-accelerated the tape to fresh 52-week highs near $92, and the 2026-06-17 Cushing's relacorilant resubmission (~Dec PDUFA) adds second-approval optionality. But a fresh entry…

Deal-arb thesis is now spent: the $100M Apotex asset sale closed 2026-07-01 after a 99.84% shareholder vote on 2026-06-24, so the dated binary that drove the ~3.2x off $1.85 to a $7.36 high is consumed. What remains is a cash-rich clinical…

Momentum story is dead it crystallized into Vertex's $85.00/share all-cash takeout (announced 2026-07-06, ~$10B). Shares gapped to $83.53 (+99%) and now trade as a merger-arb spread capped at $85, with ~$40 of air below on a deal-break. No…

Aero-defense superalloy pricing cycle intact (three contracts at >30% price hikes, 2026-06-14; Q4 op-income guide $205-210M, +37% YoY), and the July parabola has flushed RSI 48 from 83, price ~10% off the $619.25 ATH close on Russell…

Deal-or-no-deal special situation: the 2026-07-06 Vista/Quinti take-private bid >$50 against a ~$23 tape implies the market prices only low-teens completion odds, earned by Criteo's serial failed-sale history. The momentum pop already…

Clean Phase 1 AD binary resolved 2026-05-14 (sold off 28%), but since the ~$10 late-May low shares have re-rated ~55% to $15.67 (2026-07-10), reclaiming the 50-day as the oncology-immunology theme firms. The recovery runs into a summer…

Cyber/AI-security demand still accelerating, but CRWD's own tape isn't confirming it: the 2026-06-03 sell-the-news repair rolled back over in July, shares slipping despite split-adjusted PT hikes ($172–$235), and the 4-for-1 split (7/2)…

Solar policy-relief rally is dead CSIQ round-tripped $34.59 (May) to $14.75 (Jul 8) as the July 4 ITC deadline passed into a demand-cliff narrative. The US-HJT reshoring/45X pivot is real but a 2027 P&L event; broken below all MAs into a…

Citi Trends' value-apparel turnaround is real and accelerating Q1 FY2026 comps +13.9%, a 21-month positive streak, and a raised full-year guide but the 2026-06-02 print was the catalyst and it fired five weeks ago. On an ~8.1M-share float…

Freight-cycle inflection play where the sell-side is finally re-rating: Stephens (07-08) and Citizens (07-15) both initiated at $60, roughly double the stale $33-35 consensus. But Q1 margins moved the wrong way, insiders sold the whole…

Currency/payments spinoff re-rating into an authentication & traceability roll-up (De La Rue + Antares Vision); SAT sales +51% YoY, FY sales guide hiked to 15–17%. A June 27 Russell large-cap ejection forced a washout to ~$47.48; price is…

CGT cold-chain picks-and-shovels; the 2026 re-rate has matured. Consensus PT drifted to $15.11 (now just below the ~$15.26 spot), the rating softened to Moderate Buy with two holds added, and insiders distributed into the early-June $16.73…

June's $50M raise at $3.05 (16.4M sh) is already underwater: shares last $2.775 (2026-07-02), below the offering floor, with ~$50M shelf undrawn and soft Q2 guidance (rev $93–95M, adj. EBITDA still negative) into the 2026-08-10 print. A…

June's sell-side upgrade wave has exhausted and the first cut printed Bernstein to Market Perform (PT $226, 2026-07-06) as the stock rolled over. AI-observability narrative intact but maturing; the $278.71 parabola round-tripped and the…

Phase 3 depression win for DT120 already ran +60% in public; a seven-shop $50–$74 target band and a $700M raise at $34 are digested, not fresh. Post-catalyst name maturing under a dilution overhang the entry is a base that holds $34, not…

The AI-server/auto power-content re-rate that carried DIOD to a ~$126 all-time high (June 18) has round-tripped: a double-top, an analyst downgrade, more insider selling and a sector-wide semi selloff pushed it to ~$96 by July 10, through…

Deleveraging-and-refranchising turnaround with a now-dated catalyst: Q2 FY2026 prints 2026-08-06. Net leverage cut to ~5.5x from 6.7x, liquidity >$300M, but revenue still shrinks and ~23-29% of the float is short. The tradeable energy is a…

Railcar-inspection shell re-rated into an AI data-center/edge-compute + behind-the-meter power operator. July-7 Nistar 2 MW MSA and Russell 2000 inclusion rebuild the story above the $9.50 secondary floor, but structure stays broken below…

CGM leader's recovery has aged from catalyst-pop to an analyst-revision grind Mizuho $90 (7/15), Truist $87 (7/16) into a ~7% two-day pop to $76.65 — but price is high-the published invalidation levels still under the 200-EMA and the…

Closed-end SpaceX proxy whose entire bull case the pre-IPO scarcity premium is now dead: SpaceX trades publicly (SPCX, $135 IPO 2026-06-12, ran to $225, back near ~$145 lows by 2026-07-10). DXYZ's premium has collapsed from ~151% (May)…

Lithium-recovery narrative that ran Elevra ~5x has rolled over. China lithium carbonate hit a 3-month low (CNY 151,750/t, Jul 7 2026), the ASX line broke to A$8.86 (Jul 11) below its A$12.20 May placement base, and the Jul 10 June-quarter…

Post-Colfax orthopedic pure-play turnaround: LimaCorporate integration plus FCF-conversion recovery (43% in 2024 toward a 70–80% target) is the self-help story, but price has rolled over from $34 toward $27 while three brokers cut targets.…

IQ SST AI-data-center pivot (announced 2026-04-28) that drove a spring squeeze has stalled stock de-rated ~16% in a month to ~$45 (2026-07-09), sell-side uniformly neutral with PTs on top of price (Susquehanna $45, 2026-07-10), and SST…

WFE-upcycle consumables re-rate now MATURING: after a +30% two-week run to ~$181 on the JSR/Inpria EUV cross-license and CNBC coverage, July sell-side is splitting Mizuho to $200 (07-01) vs Deutsche Bank Hold $155 (07-06), BMO $167 with…

A rejected $30/share Yellow Wood bid (2026-06-22) flips EPC from dead-tape value-trap to a live take-private special situation the board refused outright as too low and shares gapped +18% to new highs near $27. The leg being bought is M&A…

Best-in-class pan-RAS efficacy (ERAS-0015: 62–75% NSCLC ORR) already discounted through a ~48% post-print crash; stock round-tripped from ~$10 to ~$16 into overhead supply while the RevMed '225 patent fight and a securities class-action…

ARCHIMED take-private cleared its last binary: the 2026-07-08 vote adopted the deal (135.3M for vs 22.8M against), and with HSR and German antitrust already done only the mechanical Q3 close and Nasdaq delisting remain. Stock is pinned at…

Q1 beat-and-raise (adj EPS $0.14 vs $0.09, FY26 guide lifted above $120M, 2026-05-14) confirmed the specialty-pharma rollup, but the story stopped accelerating in mid-May and now drifts through an empty window into the ~August Q2 print the…

Smadex AI-DSP re-rate is real ATS net revenue +204% YoY in Q1 2026 but the move has matured into a tight consolidation on ~77% lighter volume with no dated catalyst until the ~early-August Q2 print; the TelevisaUnivision affiliation expiry…

Matured auto/home insurance lead-gen cyclical that re-rated on the tape: a +6.91% breakout on 2026-06-26 (~4x average volume) reclaimed the declined ~$20.30 200-DMA, confirmed by a live estimate-revision cycle (Zacks consensus EPS +21% in…

The late-June retail bounce has fully unwound EVH traded ~$5.76 on 2026-07-07, back under the $6.59–6.86 consensus target band and well under Truist's flat $7. Nothing carries the name now except the confirmed 2026-08-06 Q2 print, which is…

Declining expense-SaaS attempting an agentic-finance re-rate: MCP launch (Jun 8) + Concierge AI agents (Jul 1) are the narrative leg, but the core is still shrinking revenue -6% and paid members -4% YoY in Q1 (May 7). The 2026-08-06 Q2…

Legacy campus-networking name re-rating ~+140% off Feb lows on the Platform ONE / Agent ONE AI-NetOps story plus SaaS ARR +29% YoY; theme still ACCELERATING but spot ($33.71, 07-10) has run through consensus PT $29.06 into the June bull…

Sterling-integration turnaround already re-rated FA tripled off an $8.82 low to ~$22 and now sits above every sell-side target into an Aug 6 Q2 print, with June hiring softening (57k vs 129k) threatening the volume base. Late-leg, not…

Freshly de-SPAC'd solid-state battery name has fully unwound its debut mania down ~78% from the $25.33 ATH to ~$5.67, breaking clean through the former $9.26 floor into a fresh 52-week low at $4.24. Cantor's $18 target now sits ~217% above…

Activist-plus-new-CEO turnaround has stopped accelerating and started digesting: after the +30% run off Garden's $40.6 buy, price has chopped $50–54 for three weeks while sell-side targets climbed past spot (Goldman $61 on 7/10, Barclays…

Data-center-power narrative intact, but the June re-rating just met a $225M equity raise (10.71M sh at $21.00, July 8) that capped the move; a Siemens design/supply partnership (July 9) stabilized the tape, yet a fresh entry near $21…

Legacy-CCaaS AI pivot staged a sharp V-recovery: +29% off the $19.70 June swing low to $25.42, reclaiming the broken $22 shelf on a 2026-06-23 next-gen Voice AI Agents launch and an AI-first leadership overhaul. Now pressing the $26.26…

AI-manufacturing re-acceleration: the 2026-07-09 Cerebras CS-3 production expansion is the first company-specific bid since the S&P-inclusion +6% pop round-tripped to ~$147, refreshing the data-center power/EMS narrative into the ~07-29 Q1…

Narrative and price have fully decoupled: FLY stacked a $144M CLPS award, a Moon BASE seat and a $13M Mars subcontract into a -47% drawdown, falling 9.6% on 7/16 on the awards headline itself. At $19.27 vs a $45 IPO price and 31% below the…

Optical cluster re-accelerated in July (AAOI +390% YTD, LITE +138%, COHR +107%) while Fabrinet sits ~$478, +0.7% YTD and ~36% under its $748.89 high. Revenue compounds at +30% but the tape has decoupled from its own theme a…

Payments roll-up at ~$50, a hair above its $46.26 52-week low set on a 2026 guide-down. The Global Blue tax-free-shopping integration ("Shift4 One," launched 2026-07-14) is the transformation leg, but the 2026-07-30 Q2 print is the binary…

Second secondary in five weeks ~43.6M shares at $49 on July 2, now including company primary dilution confirms the recurring-supply pattern and dragged the stock from its $65.56 June-4 ATH back to the offering line. The…

Tariff-driven HRC steel prices at multi-year highs powered record FY2026 (EPS $2.76, sales +46%); FRD hit an all-time-high close $37.42 on 2026-06-18 and was flagged overbought the same day. The narrative is maturing and priced near the…

July re-stacked a capped bull cluster Deutsche Bank Buy $272 (07-07), Morgan Stanley OW $245 (07-09), Susquehanna Positive $270 (07-10) yet every target sits at/below the June $305–310 high, and a third "10-year returns" retail piece…

Cyber-software leader still pinned near its $151.97 ATH, ~+60% YTD, but the sell-side has split at the highs: BTIG chased to a $186 PT (2026-07-10) while HSBC cut to Reduce (2026-06-30), the first outright downgrade. Theme SATURATED, no…

CRO margin-turnaround already re-rated FTRE ~4x off its 2025 low; the Q1 beat that drove it is spent and price sits ~9% under the $18.67 52-week high, above most analyst targets. Fresh positive drift (Zacks Strong-Buy 7/7 on +31% estimate…

Busted-merger workout losing its bid: the +48% June bounce to $14.87 (on a speculative Amazon-bolt-on thesis) has faded ~13% to ~$13, whole-company sale is now reported "unlikely," and the 2026-07-10 chairman exit forfeited…

Signed $9.50/share cash take-private by Long Lake (~$6.3B; General Catalyst + Alpha Wave backed); 69% of shares locked via voting agreements, close guided 2H 2026. Stock pinned ~$9.36 pure merger-arb with ~1.5% capped upside vs ~37%…

Alternatives-manager re-rating: infrastructure and private-credit fundraising (AI-power capex driven) plus a $9.8B contracted-not-yet-fee-paying AUM backlog point to fee-earnings acceleration but reported Q1 FRE was flat YoY and shares sit…

The operating turnaround is real but priced, and its one asymmetric leg the activist proxy fight lost its teeth: ISS (2026-07-07) backed all nine board directors and urged holders to withhold from the two Radoff/Jumana nominees, so the…

Legacy consumer-security roll-up repaired from $23.31 (2026-06-25) to ~$26, reclaiming the $24 shelf but not the $27.76 earnings high; fresh AI-trust-layer angle (Norton Genie into Claude, 2026-06-30) is real but unmonetized. The…

Sports-data toll-booth under the prediction-market boom, but the boom arrived and the toll didn't: Kalshi/Polymarket cleared $50B+ of World Cup volume (Coindesk, 2026-07-14) while GENI slid $6.43 → $6.30 and printed $5.98 intraday July 17.…

Post-launch broken-momentum hematology name: RYTELO 2L lower-risk MDS ramp is real but decelerating (Q1 2026 $51.8M net rev, +31% YoY) while the stock sits near its $1.04 52-week low, below every major MA. The only live re-rate is the…

AI-chip specialty/photonics differentiated vs TSM (not a dup), but Mubadala $1.91B block overhang caps upside until absorbed; clean entry is a 52w-high reclaim post-block, not now.

Argentina disinflation is still working June CPI printed 1.9% MoM on Jul 14, an improvement on May's 2.1% but the ADR faded the good print, dropping ~7% on the week to ~$50 and losing both the $51.07 50-day and the $52.86 200-day. Macro…

Premium-golf consumable franchise (Titleist Pro V1) catching a defensive-quality rotation bid; JPM's 2026-06-26 Positive Catalyst Watch (PT $96→$118, Q2 growth 11.8% vs 10.3% cons) frames the ~2026-08-06 Q2 print as the confirmation. But…

Gemini 3.5 Pro delayed months (Bloomberg 2026-07-16) the one leg differentiating Alphabet from mega-cap beta just weakened publicly, nine days before the ~2026-07-28 Q2 binary. Cloud fundamentals intact (+63% YoY, ~$460B backlog, BofA…

Sell-side is re-rating GSHD ahead of the tape: five price-target raises in eight days (Piper $52→$72, Cantor $76, UBS $70, JPM $60, RBC $55) against a stock still at $54.28 and -49% YoY. The 2026-07-22 Q2 print is the binary that decides…

Turbo cash-cow re-rated (~8–9x → ~18x) on a datacenter/industrial oil-free cooling narrative; the parabolic Feb→June leg (~$20→$36) is spent, shares faded ~11% to the 50-day near $32.30, and the ~late-July Q2 print is the first chance to…

Plasma/IVIG re-rating has stalled just under YTD highs (~$76) as sell-side finishes flipping from cuts to raises now the base case rather than an edge. Citi's July 8 "downside 90-day catalyst watch" (PT $79, Neutral) frames the Aug 6 Q1…

Q1 FY2027 (2026-07-08) beat the guided-breakeven bar Adj EPS $0.17 vs $(0.01) est, sales $402M vs $375M, sales guide nudged up and analysts lifted PTs to $25–28. The turnaround binary resolved favorably, but the stock now sits at fair…

Post-dilution CNS microcap re-firing with the psychedelic cohort (ATAI, CMPS all moving 2026-07-16) after a June social-velocity blowoff and a 10.3M-share secondary at $4.85. Both covering shops cut targets in July while holding Buy. No…

GLP-1 reaccel is a promise until the ~2026-08-10 Q2 print the first proof of the +25-28% guide off a +4% Q1 trough. Sell-side has now chased above spot (Canaccord $40, Barclays $39, BofA $37), so upgrade fuel is largely spent, CVS entering…

Post-blowoff digestion. The AI-smart-glasses display-silicon parabola topped at $24.19 (2026-06-03) and round-tripped ~40% to ~$14 by late June with no base. The WiseEye/LCoS/CPO tech is intact and a one-time ~$23–24M startup-stake gain…

BTC-miner→AI-compute re-rating has its first blue-chip proof BUZZ HPC's $220M Bell/Cohere sovereign-AI GPU deal (~$70M ARR) on top of $35M contracted ARR but the stock stalled ~$3.79 — below its early-June highs as BTC bled ~45-50% off…

Transformational Steelcase merger (closed 2025-12-10) made HNI the #1 North American office-furniture maker at ~$5.8B revenue, but the tape is broken near $40 versus ~$70 analyst targets a show-me integration grind, not an accelerating…

ROAD-to-Housing relief pop has fully round-tripped: HOV ran to $147.55 (06-26) then bled to the low $120s as the bill became law WITHOUT a signature on 07-11 the bull catalyst arrived and the stock fell. Sell-the-news is complete; two…

Hormuz war-premium oil proxy: 68%-oil Permian small-cap, ~40% unhedged into $90+ WTI, but six weeks into front-page coverage the premium is already in the strip and the binary reverses on any ceasefire. A levered, weaker expression of WTI…

West Coast office/studio REIT that nearly tripled off the April $5.51 low; operating recovery is real but the move has matured into a split $12–$16 analyst cluster with B of A now at Underperform. The trade is now a binary ~$566M CMBS…

Commercial ophthalmology special-situation trading on one number: does the guided H2 ramp print. June–July portfolio launches (VERKAZIA, BYOOVIZ) keep sentiment alive, but the binary is the ~Aug 10 Q2 report $71–81M guide vs $44.2M Q1. A…

Freight-cycle recovery has a stronger structural leg than the rate data alone implied regulatory driver purge (~194k CDLs, ELP enforcement) plus spot above contract for the first time since 2021. But HTLD is unprofitable, all six covering…

Squeeze fuse defused and now the tape confirms it: after the 06-25 raise cleared 37M shares at $2.70, HTZ printed a death cross (07-06) and Morgan Stanley cut to $3.50. Jane Street's new 5.0% stake is convertible-arb inventory, not…

Med-device turnaround re-rating is now fully banked into Hold-grade targets: BMO initiated Market Perform $19 (Jul 9) and Citi raised to Neutral $19 (Jul 8), both landing on the tape (~$18.76). The distressed-to-fair leg is done; only…

Analyst-momentum re-rating on a beaten-down CRO: Q1 2026 beat (adj EPS $2.50 vs $2.42) plus two upgrades in a week RBC Outperform $185 (06-25) and Truist Buy $207 (06-30) but price still trades below its 200-EMA and the Q1 catalyst has…

Precision-oncology name digesting a $300M raise at $27.00 (priced 2026-06-09); analysts cut targets 2026-07-07 (RBC $48, Truist $63) while staying bullish. Darovasertib uveal-melanoma registrational path is the embedded option, but the…

Data-center electrical "shovels" fundamentals still accelerating (Q2 FY26 backlog +62% to $3.9B, Communications +35%), but the June index-inclusion parabola to a ~$800 ATH expired July 1 and a 2026-07-02 shelf prospectus on a…

M&A special-sit stays the dormant leg SiriusXM talks stalled over the divestiture/antitrust impasse and unrevived but the $6.56 April spike stabilized near $4.05 instead of bleeding out, and a fundamental H2 story (2026 midterm…

Post-ASCO sell-the-news biotech: atebimetinib's 17.3-month first-line pancreatic OS is real but single-arm, and the Phase 3 OS binary is ~2 years out (mid-2028). Near-term is a coverage and base-building story with no dated OS catalyst…

Near-term regulatory binary resolved favorably FDA accepted the ozekibart chondrosarcoma BLA on 2026-06-15 (PDUFA 2027-04-14) but that docketed the defining decision ~9 months out, dropping the name into an extended catalyst vacuum.…

Automotive ADAS-silicon design-win story keeps improving on paper ($7.4B backlog, $25M radar order, ams OSRAM sensor buy) while the tape stays broken below the ~$4.00 50-day MA; TD Cowen's 2026-07-13 lift to a $4.50 Hold is a thaw, not a…

Halted micro-cap: the $39.49 last print (June 8, 2026) was a 3,660% blow-off from $1.05 on a $3M AI 'used-phone sales agent' deal, after which Nasdaq froze it under T12 and the board opened a probe into its own trading. No live tradeable…

AI training-data pure-play with a still-accelerating fundamental story (Q1 rev +54%, 40%+ FY26 guide reaffirmed 06-17) but a fully broken chart: ~-51% from the June $125.14 ATH to ~$61, with the CEO filing a fresh 200k-share sale on 07-16…

Up ~39% YTD on a rotation-into-quality-defensives bid, but FY2026 guidance is EPS $4.85 a ~5% decline as Interparfums invests through a trough year toward a 2027 license rollout. The move is multiple expansion, not earnings; sell-side PTs…

US critical-minerals sovereignty name whose funding overhang cleared the ugly way: a 2026-07-08 US$50M ADS raise priced at $21.98, ~22% below the ~$28 pre-deal level, resetting the stock to $22.94 near its $21.66 52-week low. Pre-revenue,…

Special-situation biotech, not momentum: the 2026 Linzess pricing-restructure re-rate faded to the low-$3s, then bounced ~30% to a $4.65 close July 8 on M&A speculation with no confirmed bid, since fading to ~$4.21. The Aug 6 Q2 print is…

June's move was a float mechanic Russell Microcap inclusion (effective 2026-06-30) into a 40%-short float drove $8.92 to $18.13, and it is unwinding ($14.98 on 2026-07-17, -7.76%). SSS is genuinely inflecting (-6.7% → -3.8%), but price…

Both binaries this stock coiled around have fired and are spent: JADE101's clean Phase 1 (2026-06-01, ~70% IgA reduction, q12w dosing) and Vera's TRUTAKNA accelerated approval (2026-07-07), which validated the APRIL/BAFF mechanism but put…

Fuel-reversion bull leg broke: Brent re-spiked to ~$86 (Jul 17) on renewed Mideast conflict, reversing the sub-$73 tailwind the whole trade needed. Raymond James (Jul 6) cut to Underperform flagging a Chapter 11 that wipes equity; $9.3B…

eVTOL cert story still advancing (FAA TIA testing, 2026 Dubai target) but the trade rolled over: ~$8 testing support, down ~33% since June 1, recovery base gone, CFO sold ~half his stake June 8, consolidation coverage marks sentiment…

Genuine FY2026 turnaround (loss→$3.6M net, record $166M rev) plus a +20–22% Q1 guide drove a +36% circuit-breaker gap on 2026-06-15. Three weeks on the catalyst is spent, no fresh news since June 18, RSI-88.6 momentum has bled off the gap…

Section 232 aluminum supply-shock (50% duty through 2027) plus a Q1 earnings inflection already repriced KALU ~+175% YoY to a $195 high; the move is MATURING toward SATURATED with price at/above every published target. The estimated…

Closed takeout, not a security: Chiesi's $27.00/share all-cash acquisition of KalVista completed 2026-06-11, shares delisted from Nasdaq with deregistration (POS AM, Form 25, Form 15) underway. No spread, no momentum leg, no listed share…

Former Bitfarms miner→AI/HPC-datacenter pivot has rolled over: June's push to ~$6.14 into Citizens' $10 initiation retraced to a ~$4.975 ref by 07-06, losing the $5.00 convert shelf and drifting toward the $4.00–4.20 base. Still zero…

Cyclical staffing recovery is fully printed Q1 returned to YoY growth, Q2 guided +~4% but price ran ~24% in three weeks to a fresh all-time high near $58.6, ~38% above the $42.33 consensus PT, into the confirmed 2026-07-27 Q2 print. A…

Process-control monopoly (~58% share, ~7.5x nearest rival) with an accelerating custom-silicon narrative, sold down in the worst semi month since 2008. Six analyst PT raises in eleven days but the July cluster ($255–274) sits well below…

Freight cycle has physically inflected tender rejections 17.2%, spot above contract for the first time since 2021 but the tape stalled at ~$76.68 versus a $86.63 average target. The whole trade now compresses into the 2026-07-22 Q2 print…

ABC-platform redemption arc: after the 2022 DAZZLE wet-AMD miss took KOD to $4.60, back-to-back positive Phase 3 diabetic-retinopathy readouts (GLOW1, GLOW2) re-rated it ~9x. The September 2026 DAYBREAK wet-AMD topline is the binary either…

Pension-reversion fat pitch fired and is spent; the re-rate has fully unwound from the $14.87 May high to ~$7.78, losing the $9 June shelf and printing a $4.94 52-week low. A July 1 resale shelf of up to ~39.46M shares and a June 29 Sell…

Jubilee ramping toward ~90,000 bopd gross (J76 online, J77/J50 imminent) with GTA LNG volumes climbing. Highest-beta E&P expression bounced ~15% off the $2.00 June low; re-accelerating but still a ~$2.30, 'CCC'-rated, most-levered…

Squeeze leg has stalled: Morgan Stanley's 2026-07-06 Underweight/$15 reinit broke the one-way upgrade cluster and knocked the stock -5.9% on 07-08. Price ~$17.18 still holds above the 50- and 200-day, but with the sell-side now two-sided…

Ziftomenib/Komzifti approval (2025-11-13) already de-risked the story; the Street's $24-28 targets underwrite a frontline-AML expansion gated to a 2028 Phase 3. Stock consolidates near its $12.49 52-week high on a slow launch ($5.8M Q1)…

US critical-minerals-sovereignty policy re-warming (Pentagon's $725M Energy Fuels stake, the Intel/US Steel government-equity template), but the lithium-price recovery leg is cold carbonate rolling over keeps LAC pinned to its $4.50 base.…

The 2026 lithium-recovery narrative has broken: CATL's ~46ktpa Jianxiawo mine restarted 2026-06-29, pulling the supply-discipline leg out from under the rally. China carbonate fell to a ~4-month-low CNY 151,000/t and LAR sliced its $7…

In-vivo CAR-T re-rate has matured into digestion: EHA (6/13) confirmed LB2501's 100% ORR and clean durability, but the 6/17 $226M raise at $29.35 capped the leg and JPM's 7/13 Neutral $35 reinstatement caps the Street. No fresh catalyst…

Legislative-spike homebuilder fading into rising rates: LGIH gave back over half its 2026-06-24 ROAD-to-Housing gap, closing $58.52 on 2026-07-17 as ~6.65% mortgage rates dragged the whole builder cohort lower. Q2 closings grew +8.8% YoY,…

AI-datacenter MEP/HVAC pick-and-shovel story still improving on fundamentals (record $5.38B backlog, FY guide raised to $4.1–4.3B), but the tape has decoupled: ~33% off the $102 May close high, LGN sliced the $76 breakout shelf and rolled…

Contested insurtech IPO reclaimed its $19 price in a late-June ~28% rip and has held it into a fresh JPM Overweight (PT $23, 2026-07-13). But the reclaim runs into the 2026-07-27 final lock-up and an unresolved upfront-accounting short…

Insider-cluster leg has already paid: Malone/Fries/Nair bought the post-distribution $4.98 June base, and the common is $7.34 ~47% higher in under a month. July brought Citi's downgrade to Neutral (PT $8) and a Barclays Underweight at…

Post-catalyst drift: the $500M preferred special dividend and the June Malone/Nair insider cluster already drove a ~70% run off $4.76 to ~$8.30, and the tape has stalled at $7.33. Citi cut to Neutral 2026-07-10 with a $8 target already…

AI-insurtech recovery is losing sell-side sponsorship right at resistance: a reinsurance renewal cutting quota-share cession to 18% (effective 2026-07-01) popped the stock on 2026-07-06, but Morgan Stanley pulled its FSD-thesis Overweight…

Q1 FY27 (2026-06-11) beat in a shrinking furniture category, but the tape refused the news and no volume-confirmed reclaim has fired five weeks on. With ~27–31% short float and clustered June insider buys, the only live edge is a squeeze…

All-cash takeout has closed the story. ANV Group's $3.15 tender for Open Lending went live 2026-06-29 with a 2026-07-27 initial expiry; the equity is pinned to the deal price with no momentum leg only a thin arb spread against…

Single-asset FA binary: nomlabofusp rolling BLA underway for accelerated approval on a novel frataxin surrogate, Breakthrough-designated and FDA-aligned but shares sit near 52-week lows after a -15% sell-the-news on the 2026-06-29 filing,…

The June 30 NASA Moon BASE award ($148.3M Nova-C) bought exactly one green session before the stock broke: seven straight down days into 2026-07-13 for -24.5%, -36.5% on the month, $13.80 on 2026-07-18 versus a $38.55 May high. A live…

Morgan Stanley broke the all-Hold wall on 2026-07-06, resuming at Overweight with a $30 target and a $3 EPS-power call vs ~$2 consensus the first real upgrade catalyst since the Q1 beat. But price faded the note ($23.99 → $22.64 by 07-12)…

Deli prepared-foods roll-up keeps compounding Q1 FY2027 (2026-06-08) revenue +49.7% YoY but management top-ticked the 52-week high with a $100M raise at $18.00 (2026-06-30): ~14% dilution, momentum reset, theme cooling to maturing. No…

AI/HPC power-buildout re-rate is the leg being bought the 2026-07-09 HIF deal adds up to 2 GW in Texas, lifting potential capacity toward ~4.8 GW but the golden-cross base fully round-tripped to ~$11.4 as analysts cut across the board (MS…

Once-weekly canvuparatide's 1-yr Phase 2 durability (57% responders, 12 Jun) plus a cleared End-of-Phase-2 FDA path drove a +580% YTD re-rating into all-time highs. With the data catalyst spent, no dated binary inside 30 days, and an…

AI-data-center re-rating leg is unwinding round-tripped from the $105.91 May ATH to the ~$84 50-day EMA under an unrebutted J Capital short thesis and a 2026-07-13 TD Cowen PT cut to $90; only the cyclical MCU/industrial recovery (~93% of…

Atlas re-acceleration (+29.4% YoY, record $117M seq add; Q1 FY27, 2026-05-28) is intact, but the +18.5% post-print breakout fully round-tripped from $444.72 to a $294.10 close as the AI-software theme sold on margin-timing fear. Sell-side…

Take-private process went live: WSJ reported substantive Diller talks 2026-07-10, MGM seated a special committee mid-July, and the board reportedly views $48.30 as too low so the trade is now a bump handicap, not a growth story. At ~$46.91…

Cheap cyclical furniture name squeezed ~24% off its 2026-06-24 post-earnings $17.29 close to $21.42, pressing the $23.18 52-week high but on a decelerating narrative: Q4 orders -6.3%, backlog -10.8%, a downgrade to Hold, CEO-transition…

India-OTA recovery bounce, not a fresh breakout: MMYT is +79% off the $32.67 low and just reclaimed the 200-day (~$55) after HSBC's 2026-07-02 Buy/$70 initiation but a MATURING travel theme runs straight into a binary Q1 FY2027 print…

De-risked Wilson-disease NDA melt-up extended rather than sold the EAN news: a 6.70M-share float ran to fresh all-time highs (~$111 on 2026-07-17) on the June-30 FDA Rare Pediatric Disease designation and clustered analyst PT hikes. The…

Contracted AI-cooling supplier story is intact $4B+ Airedale capacity agreement through 2029, $165M customer prepayment but the tape has unwound ~29% from the $323.25 May high to ~$229, lost the $260 base, and is -19.4% in a month. The…

Medicaid-margin-trough recovery, now fully re-rated: June's Illinois-win + BofA-double-upgrade breakout to ~$230 has matured into target catch-up (July raises to $230-250, but ratings stayed neutral and Barclays cut to $184). The whole leg…

Margin-led re-rate (Q1 FY27 GM 57.3%, +320bp; adj EPS $0.32 vs $0.08 est) is already priced at $38.65, ~3% off the $39.85 high after six weeks of chop. The live variable is the 2026-07-24 Section 122 expiry: the 10% Swiss-watch surcharge…

AI data-center power narrative still accelerating fundamentally (Enterprise Data ~2x YoY to $262.8M Q1; Q2 guide $890–910M, +35% YoY), but the tape bounced ~12% off the ~$1,200 shelf to ~$1,468 and now stalls at the 50-day into a binary…

Sympathy bid off the Micron-led memory supercycle and Russell 2000 inclusion floored the post-parabola markdown in the low-$20s, but the ~2026-07-28 Q2 print is now the binary: Everspin must show a non-casino datacenter/AI design win or…

Flu-vaccine approval story confirmed by an early-July sell-side PT cluster-raise (Piper $77, RBC $45, MS $39, BofA $34→$38), but the clean +30% momentum leg already ran into the June 18 9-0 advisory vote. The Aug 5 mRNA-1010 PDUFA is now…

Post-COVID survivor re-rate has run its momentum leg and is now digesting a parabolic +31% push to a fresh 52-week high of $6.22 (June 26). Every driving catalyst is public, the move is idiosyncratic with no life-science-tools cluster…

Custom-silicon ASIC royalty story intact, but the AI-semi theme is mid-correction chips posted their worst month vs software on record (7/17) with money rotating into energy. Buying a falling sector with no confirmed higher low is the…

AI-capex derating still in control: MSFT closed $393.82 on 2026-07-17, below the ~$414 200-day and the lost $400 shelf, -20%+ YTD, with six brokers cutting targets in one week into the print. The narrative has flipped from "spend to win"…

Housing-rebound-on-rate-cuts trade that carried MTH to a $85.38 52-week high has reversed: it lost the $75 June breakout shelf to $74.17 (-4.2% on 7/17) as mortgages held at 6.49% and Zelman capitulated to Neutral (7/7). Fundamentals still…

Beryllium critical-materials scarcity narrative still building, but the parabola cracked: a new ATH of $298.76 in early July gave way to a 5.6% reversal on 2026-07-07 to $247.20, now ~$258 and still ~9% above KeyBanc's $237 top target. The…

AI optical-interconnect arms-dealer with fundamentals still accelerating (FY26 DC growth guide >60%, Q3 guide $331-339M) but a July-broken chart: ~36% off the $418.90 high to ~$267 on the semi selloff, Russell Value index removal, and…

AI optical/interconnect re-rating is intact PTs $105–125 (Stifel/Northland/Benchmark, 2026-06-25) versus a stock that ran ~$70→~$96.60 into late June but the name now sits ~5 days from a binary Q2 FY26 print (~2026-07-23), retail coverage…

Legacy plastics maker re-rated ~2.4x on a "Focused Transformation" MTS distribution arm in discontinued ops, capital concentrated behind Signature/MegaDeck composite matting (Infrastructure orders +130% YoY, Q1 adj EPS $0.44 vs $0.28).…

Legacy hereditary-cancer testing house executing a diagnostics pivot; shares +40% off the June $3.99 base as Prolaris+AI launched (May 26) and Precise MRD colorectal/renal was pulled forward to Q3. Structure has repaired but now…

SolarWinds-spinoff MSP software vendor pivoting to cybersecurity via Adlumin MDR (26.7% of rev, +17.5% YoY); the cyber/MDR theme is accelerating but NABL's own tape is broken ~40% off, ~$4.77 near the $2.92 base low after a soft Q2 guide.…

Leveraged ~2x oil-beta proxy on the Hormuz war premium, +90% YTD near $100 — but now rolling over: Susquehanna cut its target to $85 (2026-07-08) as the sell-side stops chasing, and the ~2026-07-23 Q2 print the first to lap the premium…

Cruise complex re-rating on the fuel-cost collapse from the 2026-06-15 U.S.–Iran peace deal; NCLH is the highest-torque, most-levered name. Sell-side has now clustered ($22–25 PTs: Citi, Wells Fargo, TD Cowen), signaling the theme is…

Oncology-dx turnaround ACCELERATING NGS +26%, PTEN IHC CDx (first FDA IHC companion dx in prostate, paired to AZ's TRUQAP) launched Jul 9, and TD Cowen $14→$19 / BofA $11→$16 on Jul 13 lifted consensus to ~$15.67, back above spot. But Q2…

Cyclical zinc-recovery confirmed and fully priced: Q1 EBITDA +126% YoY and Aripuanã's record 13kt ramp drove a run to the $16.89 high, but the equity now chops $12–13 while LME zinc printed a fresh 2026 high near US$3,622 a bearish…

Newly-public consumer-measurement franchise (ex-NielsenIQ + GfK, Advent-backed) rebranding as an AI retail-media platform via a stream of partnership PRs (Unlimitail, Ogury, Lula; Jun–Jul 2026) with zero disclosed revenue impact. Narrative…

Post-capitulation base attempt, not an accelerating narrative: the 2026-06-30 print cleared a floored bar off the $41.35 low, but 2026-07-01 brought target cuts across eleven-plus desks with the average compressing to the low $50s the same…

AI-networking legacy re-rate extending on a harder catalyst leg first commercial AI-RAN platform with Nvidia (07-15) plus Taiwan Mobile, Orange Belgium and NestAI defense wins. Theme ACCELERATING, but the 2026-07-23 pre-open Q2 print is a…

AI-native private-flood MGA disrupting the federal NFIP; a rare profitable insurtech (57% adj-EBITDA margin) but revenue growth is decelerating 34%→29% and the sell-side is already fully engaged, with consensus PT $31.23 sitting at/below…

Genuine VAR margin-mix turnaround (Q1 GM +240bps, cloud GP +35%) but a derivative AI tag: hardware GP guided flat, sales +1%. Range-bound $102–123 since the early-June rejection; ~$110 already sits above the ~$103 street target with a…

Post-lockup washout in a 28%-growth SASE/SSE leader: NTSK trades ~$12.78, ~45% below its $23 debut, at roughly 3x EV/S while ARR compounds 29%. The mispricing is real, but the chart is broken below the 200-day a base-and-reclaim candidate,…

Re-rating leg has stalled: NUTX closed $162.98 on 2026-07-17 after five straight down days, ~20% off the $204.00 high, giving back the June breakout that B. Riley's 2026-06-26 Buy/$290 initiation topped out. A $55.0M true-up of 18,950…

Precision-oncology momentum story resolved into an all-cash takeout: GSK's tender at $124/share (commenced 2026-06-24) pins NUVL to the deal price. It is now a merger-arb spread, not a narrative to ride every June downgrade reset its price…

TRIDENT's OS miss (2026-06-18) killed the re-rating leg the 2026 markup was built on; JPM's 2026-07-13 reinstatement at Neutral/$17 confirms sell-side capitulating toward the ~$15-16 tape. A +12% YoY, loss-making single-asset device name…

Overbought low-dollar turnaround bounce running straight into a binary ~7/31 earnings print. The only bullish flow, a 6/10 sweep of Jul-17 $5 calls, expires two weeks BEFORE the report a short-dated $5-reclaim bet, not an earnings…

Legacy steel-pipe maker re-rated into a water-infrastructure + precast roll-up on a record $373M WTS backlog, an ~83% Q1 beat, and the Permalok RBJ field win. Narrative intact but the setup is extended last near $148, ~35% above the ~$109…

Analog/auto up-cycle re-rate in an "AI beyond Nvidia" jersey: estimates rising (TD Cowen $340, B of A $310 on 7/13; Citi $370) into a broken tape ~$266, down ~22% from the 5/27 ATH and ~12% below the $302 Street average, printing fresh…

Broken DTC-beauty flywheel: IL MAKIAGE's ad-acquisition engine seized on a CPA blowout, Q1 first orders -50%, stock crashed $77→$9.25. The ~$18 bounce sits above nearly every Street PT ($8–$12) into a Q2 print (~mid-Aug) still guided…

Freight-cycle recovery led by the top-margin LTL name is now drawing its first upgrades into strength (Evercore to Outperform $237, Jul 1; Goldman Buy $235, Jun 23), but growth is still fuel+price with tons/day -3.8%, targets sit at spot…

Takeover binary is resolved and deal-pinned: OGN trades ~$13.51 into Sun Pharma's $14.00 all-cash offer, a ~$0.49 (3.7%) gross spread. The 2026-07-06 disclosure suit was mooted by 2026-07-17 supplemental proxy filings, clearing the path to…

Closed by event: the Henkel all-cash takeout completed and OLPX was delisted from Nasdaq on 2026-07-07, with each share converted into the right to receive $2.06 cash. There is no longer a listed security, no price series, and no thesis to…

Post-CHMP-rejection repair, not a new leg: shares have clawed back from the 2026-06-26 gap low of $8.67 to roughly $9.69 on the J1289 J-code going live 2026-07-01. The 2026-08-13 Q2 print is the whole trade consensus ~$11.6M net sales…

The AI-power re-rate is unwinding, not consolidating: ON closed $87.37 on 7/17, below the 6/26 Synaptics deal-gap floor, with targets cut twice in three weeks (TD Cowen to $95 on 7/13, Mizuho to $125 on 7/1). Merger-arb supply plus a fixed…

Drone theme re-accelerated on AVAV's 2026-06-30 Q4 blowout; ONDS stacked the ~$875.8M DZYNE deal (07-06) and raised FY2026 guidance to ≥$525M but registered 39,999,998 resale shares the same day. Heavy short interest plus repeat whale call…

Flow-plus-squeeze trade into a fixed date: Russell 3000 inclusion (effective after close 2026-06-26) stacked on a 13.3%-of-float short base and the CEO warrant short-trap, against a deteriorating iBuyer (Q1 rev -38% YoY, Q2 guide ~20%…

mCRPC PRC2 story de-risked as rinzimetostat enters registrational Phase 3 (Himalayas-1, 2026-07-14) with Bayer supplying NUBEQA and a J&J-backed enozertinib lung program behind it. But pivotal data is 2028+, so the only near-term mover is…

Squeeze leg broke: +43% in four sessions to a $63.79 high, then management priced 3.62M shares at $55.22 (~8% discount) and closed ~$191.9M net on 2026-07-06. Price round-tripped to $37.04, under the 20- and 50-day and under the $49…

Independent refiner ripping on a record 3-2-1 crack spread (~$70/bbl, 2026-07-16) and the Iran/Strait-of-Hormuz premium; sell-side chasing with PT hikes to $80–85. Narrative accelerating, but price sits at the 52-week high on peak-cycle…

Beaten-down bill-pay compounder: Q1 2026 revenue +30.2% YoY yet shares carved a $20.11 June 52-week low on margin-mix fear. Now ~40% off that low into a binary ~Aug-4 Q2 print the read is a recovering base, not a chase.

Merger-arb is the entire story now: Nuvei signed a definitive all-cash deal at $7.40/share (announced June 15), taking PAYO private with close pushed to mid-2027. The narrative re-rate is spent ~4% spread left to the deal price against…

Pure merchant refiner, the highest-beta play on crack spreads. Narrative is a refining-margin shock ~10% of global capacity reported offline plus renewed Hormuz tensions driving a fast sell-side PT re-rate ($39→$58 in 19 days). But it is…

PBI broke the $17.62 shelf to a fresh 52-week high $18.62 (Jul 16) the buyback/cost-cut re-rate is now extending, not consolidating. But revenue still shrinks ~3% YoY, consensus PT $16.43 sits below spot, and Q2 prints after close Jul 29.…

Post-dilution repair story: the June 10–15 raise (~$145M equity + $287.5M 4.75% converts, ~$11.08 conv) roughly halved the stock to ~$8 while the commercial ramp (Q1 record 8.4M-lb output, +161% revenue) held. The 2026-07-15 Mitsui/RM…

Yield-analytics software re-rated on a real margin step (operating margin ~18%→25%, Platform rev +36% YoY), but the ~+280% run printed a fresh $69.05 high on 2026-07-02 and reversed 11.5% in a day to ~$59 still at the top of the $54–59…

Travel-reopening laggard flipped to a live re-rate: PEB broke its mid-teens base to a 52-week high ($19.75) as three desks lifted targets Truist to $22 (2026-06-29) off its first roadshow since 2019. The discount-to-NAV gap has largely…

Post-correction RAIN RFID recovery has extended to $138.37 (2026-07-17), holding the reclaimed $128 April gap-fill and pressing the $144.57 post-earnings high but the entire near-term read is the 2026-07-29 Q2 print (guide $103–106M, EPS…

Recovery leg re-fired: $66.06 (2026-06-05) → $71.49 on 2026-07-15 (+5.9%) → $73.20, back within 3% of the $75.25 high and ~6% ABOVE the $68.80 consensus target. Wells Fargo's 2026-07-10 note flags June financing data accelerating into a Q2…

Travel-leisure-reopening (ACCELERATING since 2026-06-17) already re-rated PK ~40% off spring lows to ~$14.42, pressing the 52-wk high $14.95 and the $14.16 avg consensus PT. Q1 FFO $0.45 beat $0.39; FY26 guide $1.74–$1.90. The laggard has…

The 2026-06-15 binary resolved against the bulls comps -5.4%, revenue -1.5% YoY to $559.2M, EPS $0.16 vs ~$0.60 consensus and the short-covering squeeze round-tripped to ~$11.30. No catalyst until the ~September Q2 comp print tests the…

Grid/AI-power second-order narrative has gone mainstream Cramer spotlighted PLPC on 2026-07-15 and the stock is ~5% lower two sessions later at $327.43, now -21% from the $414.35 ATH. Failed breakout plus Russell Value deletion plus a…

Sell-side discovery leg is spent: three Strong Buys with a $30.67 average against $28.68 (2026-07-17) leaves ~7% to consensus. The July 13 warrant redemption cleared the last dilution overhang, but the de-risking AFib endpoints are 2027…

Special-situation setup: an April-2026 strategic review (Morgan Stanley engaged) puts a possible sale on a controlled, down-~90%-from-IPO name, while record DTC revenue (+62.8% YoY) and Disney Solitaire drove a Q1 guidance raise. The Aug 6…

The +475% hydrogen-comeback squeeze has broken: the $3.12 Q1 gap and the 50-day both failed, price is ~$2.17 (-20% in 30d), and Susquehanna cut its target $3.75 → $2.50 on 2026-07-10. The June 30 NY Gateway close resolved as a restructure…

The 800VDC AI-power re-rate has cracked. POWI lost the $74–78 May breakout shelf in a -20% week to $70.45 (2026-07-17) and now sits below the $76.20 average target for the first time since spring. The GaN cohort broke with it NVTS is -41%…

Grid + AI-data-center power orders still accelerating (Q2 orders +97% YoY to $490M, 1.7x book-to-bill, record $1.8B backlog, plus a post-quarter >$400M data-center order; Street Q3 EPS revised UP to ~$1.47), but the theme cooled to…

Rig-reactivation cyclical is basing, not broken: June averaged 95 US rigs (vs ~90 Q2 guide), the July EIA STEO lifted 2026 Henry Hub to $3.67, gas rigs turned up 122→126, and Piper upgraded to Overweight 07-14. Price bottomed $8.57 (07-01)…

Profitable e-commerce-acceleration hypergrowth (Q1'26 rev +43%, NRR 127%) that went parabolic off the June Russell inclusion; now ~20% above the $22.88 average analyst target and overbought into the 2026-08-05 Q2 print. The narrative…

Post-print wreckage, not a turn. FY26 EPS held only via a ~$100M one-time tariff refund while the revenue guide went flat (2026-06-03, −25% overnight); BofA capitulated to Underperform/$70 on ~50% EMEA exposure (2026-06-25). The bounce to…

Deal-rumor re-rate has already run: $13.79 (Jun 26) to $17.38 (Jul 17), +75% off the $9.92 low, on an unsigned ~$1.5B point-of-care divestiture. Sell-side chased it up (Citi $13→$18). The Aug 4 Q2 print is the binary, and a shrinking base…

Merger spread, not a story: SWKS collapsed ~25% on Apple iPhone content loss, dragging implied deal value ($32.50 + 0.960 SWKS) from ~$102 to ~$87.7 while QRVO sits $85.50 under 3% left for underwriting a China SAMR Phase II review with no…

The eFPGA/defense royalty squeeze has fully unwound: QUIK is ~$13, roughly 47% below the $24.33 June high, and the $18 shelf broke exactly as the Russell inclusion passed. July's post-quantum IP announcement drew no bid good news into no…

FDA's 2026-06-17 reversal put AMT-130 on an accelerated-approval path with a Q3 2026 BLA the narrative is genuinely repaired, but the move is spent: $40.25 (7/17) sits below the $45.50 June offering price with the CEO selling into it on…

Merger-arb stub, not a momentum vehicle: the Publicis $38.50 all-cash deal now has a dated shareholder vote (2026-08-17, 66⅔% threshold) and HSR filed 2026-06-11. At ~$37.82 the remaining spread is ~1.8% into a year-end close, against…

Post-setrusumab-failure reset is now a cleaner two-shot gene-therapy story: DTX401 (GSD Ia) PDUFA ~Aug 23 and UX111 (Sanfilippo A) PDUFA ~Sep 19 are paired binaries, with Angelman GTX-102 Phase 3 topline due H2 2026. Stock ran ~50% into…

Broken growth compounder: the age-verification rollout throttled DAUs and forced FY26 bookings guidance down to +8-12%; stock is -66% from its $150 high and below the 200-day. The 2026-07-30 Q2 print is the binary it needs a DAU inflection…

Post-crash gene-therapy rebuild: first commercial approval (KRESLADI/LAD-I) plus a non-dilutive $180M PRV sale (closed 2026-06-12) fund it into Q2 2028, but the real re-rate is the undated H2 2026 RP-A501 Danon update a binary on a program…

Post-SpaceX-IPO space deflation has broken every support: RDW lost the ~$10.40 July shelf and prints ~$8.51, ~67% below the 5/28 record close. The $500M ATM is now ~59M shares (~25% of float) versus ~27M at its $18.57 June reference…

Luxury-resale turnaround has reached a real profitability inflection Q1 2026 (reported May 7) GMV +24%, revenue +19%, adjusted EBITDA tripled to $13.1M, FY guide raised. But the re-rate off the $4.91 low is largely spent: range-bound near…

Hypergrowth brokerage story has decelerated (Q1 rev +32% vs 70%+ historically, a forecast miss) and the stock sits near 52-week lows after the $880M RE/MAX deal spooked investors on dilution. The read is now a binary consolidation bet, not…

The oncology-pivot re-rate (0.55 to 8.00 in twelve months) has stalled: RLMD lost 10.5% on 2026-07-16 and another 4.0% on 2026-07-17 to $5.24, unwinding the Russell-inclusion bid with no dated NDV-01 catalyst before end-2026. Story intact,…

Memory theme is ripping Micron +68% YTD with HBM sold out through 2027 but Rambus has decoupled, down ~42% from its 2026-06-03 high of $174.10 to $101.44 while the cycle proxy sits near records. Interface content is a DIMM-unit story, not…

Growth is gone Q1 2026 revenue -0.3% YoY and Q2 ARR guided down to ~$820M so the only live leg is a take-private: Jana at ~10.3% forced a review and Goldman/JPMorgan are shopping RPD to Advent, Bain. A cheap-FCF LBO target holding above a…

The sell-the-news break is now confirmed: RUM lost the $6.46–$6.66 100/200-day shelf and closed $5.76 on 2026-07-17, -19% from the post-rebrand tape and within 25% of the $4.62 52-week low. Every moving average is overhead. The 2026-08-10…

Post-interim re-rating has fully decayed: $4.61 on 2026-07-17 vs the $5.14 late-June high, with no dated event between here and the upLIFT full topline in 2H-2026. A binary rare-disease name in its dead zone the 6/8 responder signal is…

June's +20% deleveraging bounce has fully round-tripped: $1.99 (6/26) back to $1.73 (7/17), now under the 50-day near $1.79 after failing exactly at the $1.99 consensus PT. Balance sheet is fixed, narrative is not accelerating, and a…

Agentic-identity story intact and the post-earnings flush is basing: SAIL clawed from a $13.33 low (6/22) back to $15.68 (7/17), a higher low off the $10.30 bottom. Growth decelerated (ARR +26% vs +30%) and guidance was only affirmed, so…

Type-1-diabetes functional-cure narrative: UP421's no-immunosuppression islet transplant is still producing insulin at 14 months (n=1), de-risking SC451's IND guided "as early as 2026." Rare-disease cell therapy is accelerating, but the…

Legacy-EMS AI re-rate (AMD/ZT Systems datacenter manufacturing) blew off to a $282.72 ATH then corrected ~16% off the highs; the est. ~2026-07-27 FQ3 print is now ~9 days out and is the binary it tests whether FQ2's +102% YoY surge was H2…

Highest-beta space-narrative small-cap (~+496% YTD, 15.6% short) whose dominant SpaceX-IPO catalyst sold off (2026-06-12, -11.44%). Rocket Lab's $8B Iridium deal (2026-06-29) re-fired the theme, but SATL is a sub-scale, GAAP-unprofitable…

Only year-long implantable CGM, clinically de-risked at ADA 2026 with revenue +71.9% YoY TTM and the tape has spent six weeks grinding back toward the $4.79 post-catalyst low ($5.11 on Jul 17). Accelerating fundamentals against a broken…

Oral-GPCR platform narrative has matured from accelerating to extended after a ~3.5x run to an all-time high of $37.99; the ENDO 2026 visibility event came and went and the tape now sits in a catalyst vacuum, with the first real binary…

Online-styling turnaround printed a 5th straight quarter of growth and first sequential client gain (Q3, 2026-06-10), but the stock round-tripped the post-earnings pop back to ~$3.85 amid insider selling and a fresh Mizuho Underperform ($3…

Cyclospora outbreak crushed SG from ~$9 to $6.15 (Jul 16) on guilt by association; FDA traceback cleared it Jul 17 (source: Taylor Farms iceberg at Taco Bell), sparking an 18% bounce to ~$7.08. Now below the $7.92–$8.43 consensus with…

April denifanstat/acne breakout round-tripped to the $6.00 Series A offering floor; SGMT bases near $7 (last close $7.06, 2026-06-26) with no trend. Dermatology pivot (China NMPA acne NDA accepted Dec 2025, US IND due mid-2026) is real but…

Tariff-recovery leg has stalled into a $39.71–$47.11 range with insiders selling every rally and zero buys; the whole story now hinges on the confirmed 2026-07-30 Q2 print. Consensus targets sit at or below spot ($43.75, 07-16), adjusted…

SI-joint-fusion grower adding a Smith+Nephew pelvic-trauma distribution leg; tape has firmed from broken to basing and is now testing the ~$17 200-day resistance shelf. Still a mid-teens grower (+11.2% Q1), not hypergrowth the ~2026-08-03…

Russell-add passive bid printed and faded after the 2026-06-26 close, and SpaceX now trades publicly (SPCX), gutting the proxy premium; SIDU has round-tripped to ~$2.16 from the $5.08 offering with an active short campaign and no dated…

MEMS-timing picks-and-shovels story is fundamentally intact Q1 datacenter revenue +158% YoY to 67% of sales, Renesas timing deal closed July 1 but the momentum leg has broken: ~$550 on July 18 is ~39% off the May 11 all-time-high close of…

Korea AI-infra narrative is loud while the ADR bleeds: $46.00 (06-02) to $30.62 (07-17), and both the 15GW plan (07-05) and JPMorgan's Overweight upgrade (~07-16) failed to hold a bid. The story flipped from AIDC margin accretion to ₩140T…

Specialty E&S compounder printing 20%+ operating ROE with Apollo's Lloyd's platform now integrated; the low-$40s-to-highs re-rate is a MATURING move that ran to RSI ~89 into late June. Next real binary is the Aug 4 Q2 print a fresh chase…

A record short squeeze (~32% of float) and buyout speculation, now joined by sell-side PT hikes (Alliance Global $10→$25, Jul 17), have carried SLS to a $16 test and back to ~$13; the defining Phase 3 REGAL overall-survival readout stays…

Dilution leg has broken the story: the $7B raise cleared at $27.50 on June 11 and spot is $24.18, with a live $2B ATM as forward supply. DDR contract prices +32% QoQ crush a business guiding 8.2–8.4% gross margin. Falling knife under all…

Single-asset ivonescimab binary sitting $1.26 — above its $12.55 52-week low with going-concern language on the record. The narrative leg is dead but the funding question changed shape: co-CEO Duggan bought 3.81M shares at $13.12 on Jun 12…

AI-interconnect fundamentals still accelerating (Q1 FY27 data center +85% YoY, Needham reiterated Buy/$200 on 2026-07-13), but the price leg has broken: -22.7% in a month to ~$125, through the 20- and 50-day, ~30% off the $177.35 high.…

Legacy web-analytics SaaS (IPO $22, now ~$7) repositioning as an LLM-data supplier: a seven-digit AI training-data contract (disclosed 2026-05-18) plus AI Agents launch is the re-rating story. But Q1 2026 growth decelerated to +10% YoY and…

AR-pivot flagship the $2,195 SPECS glasses (2026-06-16) was rejected by the tape (−4%, design panned), and sell-side is now cutting targets DOWN through $5–6 (Wells $5, DA Davidson $5, Goldman $6, first week of July) into a hardening…

Memory supercycle unwinding: SNDK is -40% from its June peak and -25% in the week to 2026-07-17, driven by a Chinese memory IPO filing (7/16) and Kimi K3's cheap-compute shock (7/17). The 8.1x forward multiple is peak-earnings cheap, and a…

Freight-cycle recovery is accelerating national truckload spot at a cycle-high ~$2.82/mi and tender rejections ~13% (a 4-year high) but SNDR rolled ~7% off its $38.66 June high to ~$35.80 while its own P&L (Q1 adj EPS $0.13, ops income…

The split-momentum leg is dead. SNEX round-tripped from a $139.01 all-time-high close (2026-06-18) to $102.99 on 2026-07-17 down 12.5% in a week, 22.4% in a month while insiders dumped $94.2M over three months with zero buys.…

Space-launch-satellite theme re-accelerated into July (07-06), yet Spire trades as its smallest, highest-beta laggard. Live legs: a European defense pivot (Diehl Defence MoU 06-10, Munich 100-sat/yr line) and residual SpaceX-IPO proxy flow…

The single event the name was priced around a July no-prior-auth formulary add for neffy came and went with no coverage win (2026-06-25 update). ARS pivoted to opex cuts ($248M guide) to defend 2027 breakeven as the stock sank and Leerink…

plus an active SDNY fraud class action keeps the stock below all MAs, churning $13–16. The ~Aug 4 Q2 print, first since the short reports and first with Kalshi, is the binary that decides which narrative wins.

China EVO+ recovery leg is decelerating: Q2 prelim (2026-07-16) of ">$90M" was in-line, sequentially below Q1's $93.52M, and drew an 8.8% gap-down that broke the $29.43 50-day. Triple-digit YoY comps end here, the M&A binary died at the…

The June AI-data-center re-rating has failed its retest: $62.06 on 2026-07-17 is -22% from the 2026-06-22 high of $79.82 and back under the early-June breakout base, with a $1.5B convertible overhang and a 7% selloff that ignored a BofA…

Picks-and-shovels contractor for the AI data-center buildout; fundamentals still fire (Q1 rev +92% to $825.7M, FY26 EPS guide $16.50–17.15, $6.5B backlog) but the June-4 blowoff has de-rated ~36% to ~$635 in a sector-wide E&C selloff. The…

Single-asset binary now inside its own catalyst window: the STRO-004 (DAR8 Tissue Factor exatecan ADC) Phase 1 readout was guided "mid-2026" and that window is expiring undated. Price has gone flat at ~$29.7 for four weeks after the June…

Busted-IPO turnaround leg re-accelerating: +30.5% in June on a Q1 profitability inflection plus live experience-economy catalysts FIFA World Cup resale, FestProtect launch, Einhorn's new stake, Guggenheim Buy initiation. At ~$12.82 it…

Milei disinflation trade in its grind-higher delivery phase: May CPI cooled to 2.1% MoM, the peso is stable, and JPM lifted its target to $13 (2026-06-25). But SUPV the highest-beta Argentine bank ADR chops mid-range near $9.57 with no…

Busted-IPO thrift retailer grinding a base on consumer trade-down plus a June 2 debt-cost cut; the June 27 Russell index deletion pulled the passive bid and capped the bounce near $10, and no hard catalyst lands until the ~Aug 7 Q2 print.…

Coal-policy sympathy trade is fully dead: SXC has gone nowhere for three weeks, $8.39 on 2026-06-27 to $8.37 on 2026-07-17, pinned to the $8 shelf with no narrative velocity. The only live variable is the Q2 print, pulled forward to…

All-stock takeout capped the story and the acquirer de-rated: ON's ~19% announcement drop and slide to $87.37 cut the 1.350-ratio implied value from ~$160 to ~$118, with SYNA at $114.05. What's left is a 3.4% gross spread to a mid-2027…

Terminated, not traded: the IKS Health merger closed 2026-07-09 at $26.25/share cash after the 2026-07-07 vote passed 11.31M for / 8,818 against. Shares were cashed out and delisted from Nasdaq. No tradable equity remains; the ticker is a…

Fallen-angel telehealth turnaround re-rating off lows: TDOC doubled from its $4.40 low to a fresh $9.78 52-week high on the Walmart Better Care distribution deal and BetterHelp's shift to insurance-reimbursed visits. But total revenue…

Tariff/de-minimis "secondhand wins" narrative that drove a ~$2→$12 run has matured into a show-me story; stock rolled to ~$7 with analyst PTs being cut, and the 2026-08-03 Q2 print is the binary on whether AI-first marketplace and the new…

Closed merger-arb: shares pinned just under Merck KGaA's $73 all-cash bid (06-25, $11.3B EV, expected close late-2026/early-2027). The full sell-side has folded targets to $73 (RBC 07-09 the latest). No narrative leg left only thin spread…

Parabolic AI-test leg broke hard: $483.84 closing ATH (2026-06-30) to $322.36 (2026-07-17), −33% in twelve sessions on a memory-glut scare, with the whole $446–$550 analyst band now stranded above spot. Company guided Q2 revenue DOWN…

The AI-datacenter-landlord re-rate has stalled: TH peaked at $20.85 and has given back ~21% to $16.36 (2026-07-17) as TDR Capital affiliates distribute shares in-kind to partners, losing the $17 secondary clearing shelf while Oppenheimer…

Reform binary spent without resolving: the DEA hearing closed 2026-07-15 with only a 2026-08-17 briefing deadline and no ALJ timeline, so Schedule III is now an open-ended administrative process. TLRY printed a fresh 52-week low of $4.20…

The deep-sea-mining reshoring leg is broken: TMC has cut through the $3.93 prior 52-week low to a fresh $3.57 low near $3.74, roughly -67% from the $11.35 high, with no bid and no near-term catalyst. The decisive NOAA license decision is…

Beaten-down insulin-pump turnaround where the entire re-rate hinges on the tubeless Mobi 510(k) targeted for Q2 2026 submission, now overdue for confirmation plus gross margin scaling toward ~60% by Q4. But price is rolled over near the…

Debt refi (2026-07-09: $86M Deerfield convert → $75M OrbiMed term loan to 2031, no equity) removed the 2027 maturity wall and triggered a sell-side cluster Lake Street initiate $10 (7/06), BTIG $8→$9 (7/09), consensus $8.40. But a 24x…

Panagiotidis shipping shell (NOT lawnmower TTC) ran 1.93→8.50 on a sub-NAV/special-dividend story that is now fully paid out and closed. Six weeks of dead tape since the 2026-06-05 payout ($3.8M cash + 5,707,246 NEW shares); on a true…

Clinical binary printed clean (2026-06-22: 100% milestone response N=12, zero treatment-related SAEs) but the next catalyst slipped to H1 2027 pivotal six-month interim AND FDA BLA-pathway feedback both guided to the first half of next…

Momentum leg snapped: after a fresh ATH ~$223.83, TTMI unwound ~30% in days (-13.2% on 2026-07-02 to ~$156) on a valuation reset, insider distribution and post-Russell-1000 rebalance flow no company news, and no catalyst until the…

FILSPARI's dual-indication ramp has fully re-rated the equity: at ~$56.71 (2026-07-17) TVTX trades at consensus PT ($52–58) and 4% under its 2026-06-25 ATH close of $59.03, having gone sideways for four weeks. The approval binary is spent;…

WFE upcycle intact fundamentally but the tape broke: -35% from the $142.59 all-time close (2026-06-30) back under the ~$95 breakout shelf on sector-wide selling with no company news. Failed breakout, no support to $80.55, binary Q2 print…

Capex-heavy self-storage buildout bolted onto a moving business throttled by multi-decade-low housing turnover; lease-up drags margins while national storage street rates soften. No accelerating narrative and a rangebound tape dead money…

Broken parabola gone flat: six weeks of $530–$570 chop after the May 8 print (GM 47.0%, rev +18.7%, but EPS $3.88 vs ~$4.42 whisper) with zero scheduled catalyst until the Q4 FY26 report on 2026-08-21. Fundamentals intact, tape dead,…

Oil-tailwind leg inverted: Brent closed 88.09 on 2026-07-17 (+14% on the week on US-Iran supply fears), erasing the sub-$80 condition that drove the June double. Price is ~26% off the 8.41 high set one day before Citi's $9 target, a 10%…

Hyperscaler dark-fiber demand turned the post-Windstream deleveraging grind into a growth story (~$1.5B disclosed funnel, $68.7M of Q1 IRU revenue from one hyperscaler), but the June re-rate to ~$11 has stalled in a three-week range above…

Late-June Iran/Hormuz flare-up flipped to a standdown Saudi supertankers now exiting Hormuz at post-truce highs (2026-07-02) and Trump says Iran 'agreed to just about everything.' USO is long the exact risk premium a signed Islamabad MoU…

Merger-arb tracking stock for Axcelis: fixed 0.3575 ACLS/VECO, both votes passed 2026-02-06, only China SAMR remains (outside date 2026-09-30). Upside is ratio-capped and the live binary is the SAMR sign-off which has run slow and may move…

The Novo squeeze is fully round-tripped and the funding answer arrived on 2026-07-02: a $21.8M at-the-market program via Oppenheimer/Canaccord. At $2.42 (07-15) that is ~9M shares against ~16M outstanding the company will now sell stock…

Networking-optical test theme still accelerating and the laggard test-and-measurement sleeve is finally re-rating: Susquehanna lifted its target to $66 (2026-07-01) and the small-cap-over-hyperscaler rotation flagged 2026-06-29 favors…

Operating numbers still inflecting (Q2 guide ~$142M, book-to-bill >2.0, backlog $300.6M) but the chart has broken: $237.62 on 2026-07-17 is ~38% off the $382.65 July high, with $271 and $300 both lost and relentless CEO 10b5-1 supply. The…

June's volume-backed reclaim to $10.03 failed to extend $9.43 on Jul 17, -5.3% on the week, with short interest rising to 11.72% of float as shorts pressed the fade. Structure holds above the 50-DMA near $8.71, but nothing hard is dated…

Last large independent obesity asset and standing M&A target, but VK2735's VANQUISH pivotal topline isn't until 2027 a catalyst vacuum into a maturing, crowded GLP-1 theme, bridged only by a secondary 3Q26 maintenance-dose readout. Stock…

Grid-transmission MATURING (fails), near 52w high but a compounder not a parabola; entry is a 20-EMA pullback, not a chase at the upper band.

Post-pivot autoimmune re-rating: Vor swapped failed cell therapy for China-approved dual BLyS/APRIL drug telitacicept (RemeGen deal, June 2025). Asset is de-risked and ~$19 sits far below the $45 average target but the global MG topline…

The precision-components AI re-rate topped at $151.78 and has round-tripped ~32% to $103.89 (2026-07-17), now below the $116.05 50-DMA after a 2026-07-13 gap-down. The narrative leg is unwinding into the 2026-08-05 Q2 print a broken…

Special-situation M&A: Bloomberg (2026-06-23) reported Varonis weighing a sale on PE interest (Blackstone/Thoma Bravo/Vista); shares ran ~$33→$42 on deal optionality atop accelerating SaaS ARR (+69% YoY Q1). Now a takeover-premium bet into…

Cycle-turn re-rate is round-tripping: down 36.4% in a month and 45.6% off $69.47, now below the $50 placement price from the 2026-06-30 dilution. Q1's 1.34 book-to-bill was real but is fully paid for at 35x forward. Structure broken,…

Two-engine KRAS oncology name: the first-approved LGSOC drug (AVMAPKI FAKZYNJA) funds the real swing oral KRAS G12D inhibitor VS-7375 in PDAC/CRC/NSCLC. Sector theme accelerating but the tape is dormant at $5.53 vs $14–18 targets; the…

Q1 blowoff (+47% on 2026-06-02, adj EPS $0.60 vs $0.32) already re-rated the equity; shares ran to a $88.57 high then faded to the mid-$70s. Activist overhang cleared, sell-side neutralizing, no dated catalyst until the ~Aug-26 Q2 print. A…

Margin-inflection turnaround: Q1 (Apr 30) printed a 5-year-best adjusted EBITDA margin of 5.2% on +7.4% revenue, and Evercore's Jun 23 hike to $100 (+9.1% session) reignited the recovery. At ~$95 the stock is mid-range ~20% under its Jan…

Beaten-down vertical-SaaS front-office platform for healthcare SMBs, down ~36% YTD and basing off the $4.24 low, repositioning around AI-receptionist monetization (TrueLark, 2025). Still a ~17% grower with GAAP losses, so the re-rate is…

Busted-growth genomics name recovering off the −49% May guide-cut crash ($170→$32); sell-side ratcheting targets back up (Guggenheim $74 Jun 29, Piper $63 Jun 23), but the ~early-Aug Q2 ARR print vs the ~$3,300 baseline is the binary. A…

First annual same-store-sales decline in 22 years (Q1 2026 domestic SSS -8.7%) broke the compounder narrative; a ~50% relief bounce off the $116 low now runs into the July 29 Q2 print the binary on the guided H2 return to positive comps.…

Subprime lender re-rated to ~30x (from a historic 6–12x) on a buyback float-shrink plus credit-normalization "growth shift," +59% in six months into a fresh 52-week high of $227.68. Now overbought, directors selling, sell-side modeling…

H2-2026 leasing inflection plus a data-center vertical guided +50% revenue, under an activist/PE takeover floor but a 2026-06-27 Russell growth-index removal forced passive selling, consensus PTs ($24.25) sit below the ~$27 tape, and the…

Quality home-furnishings compounder riding the consumer-discretionary rotation; Q1 (2026-05-21) reaccelerated every brand to positive comp and the sell-side is catching up (Evercore→$230 6/23, B of A $250 6/12). But near $226 the tape sits…

X-TOLE2 Phase 3 win (2026-03-09, placebo-adjusted -42.7%, p≈6e-12) already de-risked azetukalner and re-rated XENE from the $40s to ~$71; the story is now maturing and range-bound into a procedural Q3 2026 NDA, with the next true binary…

Beaten-down dental franchise mid-turnaround: new CEO killed the dividend to cut debt and buy back stock, but Q1 revenue was dead flat and operating margin swung negative no accelerating narrative, a Hold-rated value trap into the…

Activist-anchored distressed-deleveraging special situation that fully round-tripped the June pop: $3.49 (2026-06-04) back to ~$2.80 (2026-07-02, -9.7% on the day), now at/below the $2.50 average target after Citi cut $3.50→$2.50.…

Delisting binary resolved to the survive side: EGM passed 2026-06-29, Psyga psilocybin reverse-merger closed 2026-06-30, delinquent 20-F filed, Nasdaq listing held. ADS popped ~+90% intraday to ~$2.70 (~$6.4M cap). Now an illiquid…

Leveraged-Bitcoin-treasury proxy is a dead, de-rated narrative, and the "cheap BTC" screen is partly a float illusion: basic mNAV ~0.70x flags a discount, but fully-diluted mNAV screens ~1.3x once the Class B/convert overhang is counted…

April's YATOP squeeze (+56% to $1.77) has fully round-tripped; YAAS prints $0.731 (2026-07-02) at fresh lows below the prior $0.7503 floor. A live $6.36M Aegis ATM (filed 2026-06-26) now sells into every bounce while a re-armed Nasdaq…

Tariff-margin-recovery turnaround stalled under the $51.89 multi-year high: China now <5% of 2026 COGS and FY guide raised, but a fresh Canaccord Hold/$45 target (2026-06-23) sits below spot and the whole trade is now a binary on the…

Legacy local-listings SaaS repositioning as the brand-knowledge layer for AI answer engines (Yext Scout), but organic ARR is flat-to-negative and shares halved into a June revenue miss. Buyback-supported value trap the…

Roll-up thesis has broken. Both acquisitions closed on schedule (ALL.SPACE 2026-07-08, $300M; Solestial ~$67M) yet YSS closed $17.93 on 2026-07-17 ~45% below the January IPO range and 4.6% off the $16.93 52-week low. Wolfpack's claim that…